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leucocytes.	 However,	 this	 infiltrate	 is	 not	 able	 to	 induce	 an	 efficient	 anti-tumoural	
response.	 Recent	 studies	 have	 attempted	 to	 further	 identify	 the	 composition	 of	 the	
immune-infiltrate	 in	order	 to	gain	a	deeper	understanding	of	how	RCC	escapes	 from	




Functional	 tests	 investigating	 cytokine	 expressions	 and	 the	 migration	 ability	 of	 this	
subtype	revealed	 impaired	 functioning	of	ercDC	compared	to	conventional	DC	 (cDC).	




possible	 pathways	 responsible	 for	 differences	 between	 myeloid	 subtypes,	
transcriptomic	 profiling	 of	monocytes,	 cDC,	 ercDC	 and	Mf	was	 performed.	Amongst	
others,	regulation	was	found	especially	for	the	canonical	as	well	as	non-canonical	Wnt-




in	 RCC	 and	 microarray	 analysis	 of	 RCC	 tissue	 samples	 revealed	 that	 Wnt-signalling,	
especially	non-canonical	Wnt-signalling,	changes	with	tumour	progression.		
Functional	 tests	 of	 DC	 showed,	 that	 the	 addition	 of	 Wnt5a	 during	 differentiation	
significantly	 increases	 IL-10	 and	 IL-12,	 but	 decreases	 TNF-a	 secretion.	 Surprisingly,	
Wnt5a	also	 inhibited	the	migratory	capacity	of	cDC,	resulting	 in	reduced	motility	and	












einer	 Vielzahl	 an	 Immunzellen	 infiltriert.	 Trotz	 dieses	 Immunzellinfiltrats,	 kommt	 es	
jedoch	 nicht	 zu	 einer	 effektiven	 Kontrolle	 des	 Tumorwachstums	 durch	 das	
Immunsystem.	 Um	 die	 Mechanismen	 der	 Immunevasion	 des	 Nierenzellkarzinoms	
besser	 zu	 verstehen,	 ist	 das	 Ziel	 neuerer	 Studien,	 dieses	 Immuninfiltrat	 besser	 zu	
charakterisieren.	 Kürzlich	 wurde	 hierbei	 ein	 neuer	 myeloischer	 Zelltyp	 entdeckt,	
welcher	sowohl	dendritische	Zell	(DC)-	(CD209/DC-SIGN),	als	auch	Makrophagen	(Mf)-
Marker	(CD14,	CD163)	exprimiert.	Da	dieser	Zelltyp	im	RCC	im	Vergleich	zu	tumorfreien	
Nierenparenchym	 besonders	 angereichert	 ist,	 wurde	 er	 „enriched	 in	 renal	 cell	
carcinoma	DC“	(ercDC)	genannt.	
Bei	 unserer	 Untersuchung	 dieses	 Zelltyps	 zeigte	 sich	 interessanterweise,	 dass	







„non-canonical“	Wnt-Signalwegen.	 Auffallend	 war	 die,	 im	 Vergleich	 zu	 den	 anderen	
myeloischen	Zelltypen,	starke	Expression	von	Wnt5a,	einem	typischen	„non-canonical“	
Wnt-Liganden,	 in	 cDC.	 Darüber	 hinaus	 konnten	 wir	 immunhistochemisch	 eine	 hohe	
Wnt5a	 Expression	 im	 Gewebe	 des	 Nierenzellkarzinoms	 nachweisen.	 Auch	 in	 der	
Microarray-Analyse	von	Nierenzellkarzinomproben	zeigte	sich	eine	starke	differenzielle	
Expression	 der	 Wnt-Signalwege,	 mit	 evidenten	 Unterschieden	 abhängig	 vom	
Tumorstadium.		
Durch	 die	 Zugabe	 von	 Wnt5a	 während	 der	 Differenzierung	 von	 cDC	 konnte	 eine	
vermehrte	 Sekretion	 von	 IL-10	und	 IL-12,	 sowie	 eine	Reduktion	der	 TNF-a	 Sekretion	





Funktionalität	 von	 myeloischen	 Zellen	 hin.	 Wnt5a	 im	 Tumormilieu	 kann	 so	 durch	
autokirne,	parakrine	und	juxtakrine	Mechanismen	die	Immunantwort	gegen	den	Tumor	
modulieren.	Ein	weitergehendes	Verständnis	über	die	Bedeutung	des	Wnt-Signalweges	












melanoma,	 RCC	 is	 an	 immunogenic	 cancer	 showing	 infiltration	 by	 a	 multitude	 of	









in	 the	 treatment	 of	 RCC	 [5].	 While	 the	 treatment	 with	 IFN-a	 and	 IL-2	 have	 shown	
consistent	 results	 in	 remission	 of	 metastatic	 lesions,	 they	 have	 only	modest	 overall	
benefits	 for	 patients.	 Hence	 high	 dose	 IL-2	 remains	 the	 only	 supportable	 cytokine	






As	 RCC	 is	 able	 to	 avoid	 immune	 surveillance,	 and	 develops	 resistance	 to	
immunotherapies,	 it	 is	 important	 to	understand	 the	molecular	mechanisms	at	work.	
Some	 of	 the	 mechanisms	 involved	 in	 therapy	 resistance	 include	 the	 production	 of	
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myeloid	 cells.	 It	 has	 been	 shown	 that	 RCC	 is	 infiltrated	 with	 tumour-associated	
macrophages	 (TAM),	 NK	 cells	 [8]	 and	 dendritic	 cells	 (DC),	which	 exhibit	 impaired	 or	
differing	 functions	 compared	 to	 non-cancerous	 renal	 tissue.	 TAM,	 for	 example,	 are	
thought	 to	 contribute	 to	 immunosuppression	 and	 T-cell	 tolerance	 in	 RCC	 by	 their	
production	 of	 the	 	 immunosuppressive	 cytokine	 IL-10,	 proinflammatory	 chemokine	
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The	immune	response	is	subdivided	in	an	innate	and	an	adaptive	immune	response.	The	
innate	 immune	 system	 is	 an	 immediate,	 non-specific	 response	 to	 a	 pathogen.	 It	
comprises	a	humoral	as	well	as	a	cellular	response.	This	includes	a	physical	and	chemical	
barrier,	activation	of	the	complement	cascade,	cytokine	production	and	the	recruitment	
of	 immune	 cells	 to	 the	 site	 of	 infection.	 Leukocytes	 involved	 are	 NKs,	 mast	 cells,	
eosinophils,	basophils,	neutrophils,	macrophages	(MΦ)	and	DC.	These	cells	recognize	






The	 adaptive	 immune	 system	allows	 a	 specific	 and	 stronger	 response	 as	well	 as	 the	
development	 of	 an	 immunological	 memory.	 It	 is	 the	 interplay	 of	 two	 types	 of	
lymphocytes,	the	B-	and	the	T-cells,	which	originate	from	hematopoietic	stem	cells	in	









of	 one	 particular	 antigen	 presented	 by	 the	 host	 cell	 on	 the	 MHC	 I	 receptor.	 Upon	
binding,	the	cytotoxic	T-cell	is	activated	and	releases	perforin,	granzymes	and	granulysin	




upon	 binding	 to	 an	 Antigen-MHC	 II	 complex,	 they	 produce	 cytokines,	 which	 guide,	
influence	and	reinforce	the	activity	of	e.g.	MΦ	and	cytotoxic	T-cells.	Furthermore,	CD4+	
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T-cells	 can	 also	 develop	 into	 Treg-cells.	 These	 cells	 are	 critical	 in	 the	maintenance	 of	





lymphatic	 and	 vascular	 vessels,	 cytokines	 and	 chemokines	 as	 well	 as	 myeloid	 and	
lymphatic	 cells	 [10].	 Within	 this	 milieu,	 the	 tumour	 develops,	 is	 influenced,	 and	





cancers	are	often	able	 to	prevent	 this	and	create	an	 immunosuppressive	milieu	with	
impaired	 immune	 cell	 functioning.	 Immune	 infiltrates	 associated	 with	 this	 include	
myeloid-derived	suppressor	cells	(MDSC),	TAM,	DC	and	T-cells.		
MDSC	are	immune	suppressive	immature	myeloid	cells,	which	are,	depending	on	their	
expression	 of	 plasma	 membrane	 markers	 and	 the	 content	 of	 immune	 suppressive	
molecules,	 subdivided	 into	monocytic	or	granulocytic	MDSC.	They	are	able	 to	 inhibit	
innate	 as	 well	 adaptive	 immune	 responses	 and	 promote	 angiogenesis	 within	 the	





as	 APCs	 or	 by	 phagocytosis	 of	 infectious	 agents.	 Furthermore,	 they	 promote	wound	
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The	combination	of	 IFN-g	and	TLR	signalling	 results	 in	 the	differentiation	of	M1,	also	
referred	 to	as	 classically	 activated	macrophages.	 This	 type	of	MΦ	 is	part	of	 the	 cell-
mediated	immunity	and	has	microbicidal	and	tumourdicidal	activity.	Distinctive	is	the	
secretion	 of	 high	 levels	 of	 pro-inflammatory	 cytokines,	 e.g.	 IL-1,	 -6,	 -12	 and	 -23,	
superoxide	 anions	 and	 oxygen	 as	 well	 nitrogen	 radicals	 [12]	 	 and	 the	 expression	 of	
MHCII.	Hence,	they	are	able	to	induce	a	Th1	and	Th17	response	[16].		
M2	alternatively	activated	macrophages	were	originally	thought	to	be	activated	upon	
IL-4	 and	 IL-13	 signalling.	 However,	 as	 the	 M2	 phenotype	 is	 represented	 by	 a	
heterogeneous	group	of	subtypes,		it	is	more	accurate	to	describe	their	differentiation	
as	 dominated	 by	 the	 STAT6-transcription	 factor,	 and	 incorporating	 signalling	 from	









have	only	 recently	 been	 associated	with	M2,	 and	 are	 also	 referred	 to	 as	 TAM.	 They	





Similar	 to	MΦ	 and	 B-cells,	 Dendritic	 cells	 are	 professional	 APC	with	 the	 capacity	 to	
induce	a	primary	adaptive	immune	response	by	antigen-specific	activation	of	CD4+	and	
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CD8+	T-cells.	They	differentiate	from	bone-marrow	derived	progenitor	cells	that	migrate	
via	the	blood	into	lymphoid	and	non-lymphoid	organs.	Immature	DC	constantly	sample	
antigens	 from	 their	 surroundings,	 but	 only	 undergo	 maturation	 upon	 pathogenic	
antigen	uptake	and	stimulation.	The	complex	process	of	maturation	 includes	antigen	
presentation	 on	 MHC	 molecules	 on	 their	 surface,	 the	 down	 regulation	 of	 pro-
inflammatory	 chemokine	 receptors,	 and	 the	 expression	 of	 CCR7	 which	 facilities	
migration	towards	lymph	nodes,	cytokine	production	and	finally	T-cell	activation	[19].	
While	 acting	 as	 a	 link	between	 innate	 and	adaptive	 immune	 system,	DC	also	 induce	
tolerance	towards	self-antigens	and	maintain	tissue	homeostasis.	Simplified	there	are	
two	 broad	 subtypes	 of	 DC,	 plasmacytoid	 DC	 (pDC)	 and	myeloid	 or	 conventional	 DC	
(mDC/cDC).	 Phenotypically	 all	 DC	 express	 high	 levels	 of	 MHC	 II	 (HLA-DR),	 but	 no	





While	 summarized	 into	 one	 subgroup,	 cDC	 present	 a	 heterogeneous	 spectrum	 of	
phenotypes	with	at	least	two	general	subtypes	CD1c+CD209+/-	DC	and	CD141+	DC.	They	
respond	 to	microbial	 and	 other	 pathogens,	 produce	 high	 amounts	 of	 IL-12	 and	 can	





moderate	 capacity	 to	 cross-present	 antigens	 and	 activate	 CD8+	T-cells.	 Furthermore,	
they	 produce	 a	 number	 of	 cytokines	 such	 as	 TNF-a,	 IL-8,	 IL-10	 and	 IL-12	 when	
stimulated	[20].	 CD141+	DC	are	 infrequent,	 as	 they	only	 represent	10%	of	 cDC.	 They	
express	less	CD11b	and	CD11c	than	do	CD1c+	cDC,	but	co-express	CADM1,	CLEC9A,	TLR3	
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1.3.3 Enriched	in	renal	cell	carcinoma	dendritic	cells	
In	order	 to	 launch	an	effective	anti-tumoural	 immune	 response,	 the	 recognition	and	









–	an	additional	 sign	of	 impaired	 functionality	 [23].	 Furthermore,	ex	 vivo	 cultured	DC	
obtained	 from	patients	with	RCC	exhibited	 a	 fully-matured	 surface	with	maturation-
associated	markers	CD54,	CD80,	CD40,	CD86,	CD83	and	CCR7,	and	were	able	to	induce	




considered	 to	 represent	 interstitial	 immature	 DC,	 where	 found	 to	 be	 predominant	
within	the	RCC	and	hence	named	“enriched	in	RCC	dendritic	cells”	(ercDC)	[26].	These	
CD209+	DC	unusually	co-express	the	MΦ	markers	CD14	and	CD163,	which	results	in	a	
difficult	 demarcation	 between	 DC	 and	 MΦ.	 Functionally,	 ercDC	 show	 weak	
allostimulation	and	TH1	polarisation,	due	to	the	absence	of	specific	cytokine	production.	
Unlike	 TAM	 and	 MDSC,	 however,	 they	 do	 not	 compromise	 T-effector	 lymphocyte	
function,	as	 they	show	no	down-regulation	of	CD3e	or	CD3z,	 FOXP3	 induction,	T-cell	
apoptosis,	 inhibition	 of	 cognate	 CTL	 cytotoxicity	 or	 CTL	 cytokine	 secretion.	 They	 are	
shown	 to	 secrete	 high	 levels	 of	 MMP-9	 and	 CTL/tumour-cell	 co-cultures	 result	 in	
increased	 levels	of	TNF-a,	 and	a	 reduction	 in	CXCL10/IP-10	and	CCL5/RANTES	 levels.	
Both	TNF-a	and	MMP-9	are	known	to	be	tumour	supportive	cytokines,	which	result	in	
more	aggressive	tumour	growth	and	angiogenesis	[27].	The	chemokines	CXCL10/IP-10	
and	 CCL5/RANTES,	 however,	 are	 important	 in	 TH1-polarized	 effector	 cell	
recruitment	[28].	Furthermore,	attempts	to	in	vitro	differentiate	ercDC	from	monocytes,	
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pathway	plays	 important	 roles	 in	a	 variety	of	 cellular	processes,	 e.g.	 embryogenesis,	
cancer	development,	tissue	repair,	and	neural	as	well	as	immunological	processes	[30].	
Depending	on	tissue	milieu,	cell	type,	and	receptor	profile,	the	19	lipid-modified	Wnt-
ligands	 can	 activate	 a	 complex	 system	 of	 (Wnt-)	 signalling	 cascades,	 historically	
subdivided	into	“canonical-“and	a	subset	of	“non-canonical”	signalling	pathways.	There	
at	 least	15	different	Wnt-receptors	and	co-receptors,	 including	the	Frizzled-receptors	





whether	 they	 can	 function	 without	 a	 co-receptor.	 In	 addition,	 it	 is	 also	 difficult	 to	
distinguish	between	“receptors”	and	“co-receptors”,	as	some	receptors	can	act	in	both	
ways	 [37].	 The	 Frizzled-proteins	 are	 a	 group	 of	 10	 different	 seven-transmembrane	
domain	receptors	which	can	act	as	G-protein-coupled	receptors,	depending	on	cell	type,	
receptor	 setting	 and	 the	downstream	cascade	 [38].	 	 They	 are	 involved	 in	b-Catenin-
dependent	and	independent	signalling,	and	bind	Wnt-ligands	via	a	cysteine-rich	domain	
(CRD),	 which	 is	 also	 found	 in	 other	 receptors,	 such	 as	 the	 muscle-specific	 receptor	
tyrosine	kinase	(MUSK),	neuronal	specific	kinase	(NUSK2),	ROR1	and	ROR2	[39].	Similar	
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A	 complex	 system	 of	 intra-	 and	 extracellular	 processes,	 e.g.	 inhibitors	 and	
phosphorylation,	 decides	 which	 pathway	 is	 activated	 by	 a	 specific	 Wnt-ligand.	
Consequently,	it	can	be	difficult	to	predict	whether	a	specific	Wnt-ligand	is	a	“canonical”	
or	 a	 “non-canonical”	 ligand.	 Furthermore,	 the	 ligand-receptor	 (Wnt-Fzd)	 functional	
specificity	 is	 not	 well	 understood.	 A	 recent	 study	 showed	 that	 while	 Wnt3a	 has	
intermediate	to	strong	binding	to	most	Fzd-receptors,	other	Wnt-ligands	including	Wnt	
4,	5a,	5b	appear	more	selective	in	regard	to	their	Fzd-receptor	binding	[41].		The	current	










calveolin-mediated	 receptor	 endocytosis.	 The	 scaffolding	 protein	 dishevelled	 (Dvl)	 is	
then	 recruited	 to	 the	 cellular	membrane	 and	 co-recruits	 glycogen	 synthase	 kinase	 3	
(GSK3)	 and	 casein	 kinase	 1	 (CKIa),	which	 phosphorylate	 LRP5/6	 and	 thereby	 further	
recruit	AXIN	and	adenomatosis	polyposis	coli	(APC).	Hereby	the	b-Catenin-destruction	
complex	 (APC/Axin/GSK3b)	 is	 disrupted	 and	 inhibited,	 b-Catenin	 is	 not	 further	
phosphorylated,	and	recognised	by	the	Ubiquitin-Ligase,	and	thus	escapes	proteasomal	
degradation.	In	the	absence	of	Wnt-signalling,	Axin,	together	with	other	components	of	
the	 destruction	 complex	 GSK3,	 CKI	 and	 APC,	 orchestrates	 the	 sequential	
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1.4.2 Non-canonical	Wnt-pathway	
Apart	 from	 b-Catenin	 dependent	 signalling,	 there	 are	 also	 a	 number	 of	 b-Catenin	
independent	pathways,	 referred	 to	as	 “non-canonical”,	which	 include	 the	Planar	 cell	





The	planar	 cell	polarity	pathway	plays	a	 role	 in	epithelial	orientation,	as	 seen	during	
embryogenesis	 and	 in	 the	 structural	 orientation	 of	 multicellular	 tissues.	 It	 is	 also	
associated	with	human	diseases,	such	as	neural	tube	defect,	cystic	renal	diseases	[45]	
and	 cancer	 development.	 The	 planar	 cell	 polarity	 pathway	 regulates	 cytoskeletal	
rearrangements	as	well	 as	 the	 transcription	of	 target	genes.	When	a	Wnt-ligand,	 for	
example	Wnt5a	or	Wnt11,	binds	to	a	Fzd-receptor,	RYK	or	ROR1/2,	VANGL	and	Dvl	are	
























sensitive	 calmodulin-dependent	 protein	 kinase	 II	 (CAMKII),	 proteinkinase	 C	 (PKC)	 or	
calcineurin.	Downstream	of	CAMKII,	PKC	and	calcineurin	various	effector	proteins	are	
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A	 number	 of	 different	 mechanisms	 of	 cascade	 activation	 have	 been	 suggested.	
Following	 Grumolato	 et	 al.	 the	 activation	 of	 b-Catenin	 dependent	 versus	 b-Catenin	
independent	 signalling	 depends	 on	 the	 ability	 to	 couple	 a	 Fzd-receptor	 with	 an	
endogenous	 co-receptor	 [58].	 In	 this	 study	 it	was	 shown	 that	Dvl	 not	 only	 acts	 as	 a	
specific	 downstream	 scaffolding	 protein,	 but	 also	 as	 a	 switch	 between	 b-Catenin	
dependent	and	independent	signalling,	by	enabling	the	phosphorylation	and	activation	
of	specific	co-receptors,	LRP5/6	and	ROR1/2,	via	GSK3b	and	Axin.	Furthermore	 it	has	
been	 suggested	 that	 Wnt5a	 inhibits	 b-Catenin	 dependent	 signalling	 via	 ROR2	
signalling	[59]	 or	 the	 Siah/APC-cascade	 [60].	 Thrasivoulou	 et	 al.	 investigated	 the	
mechanisms	of	nuclear	translocation	of	b-Catenin	and	proposed	a	convergent	model	of	
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proteins	 (sFRP),	 Wnt-inhibitor	 factors	 (WIF)	 and	 Cerberus.	 DKK-proteins	 bind	 the	
















Positive	 influencers	 of	 Wnt-signalling	 are	 collagen	 triple	 helix	 repeat	 containing	 1	
(CTHRC1)	and	R-spondins.	CTHRC1,	a	secreted	glycoprotein	is	involved	in	the	selective	
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activation	of	 the	PCP-pathway	possibly	 by	 forming	 a	CTHRC1-Wnt-Fzd/Ror2	 complex	
[68]	 and	 thereby	 stabilizing	 ligand-receptor	 interaction.	 R-spondins	 can	 act	 as	Wnt-
agonists,	which	potentiate	Wnt-signalling	in	the	presence	of	Wnt-ligands.	A	number	of	
different	receptors,	such	as	the	syndecans	and	leucine-rich	repeat-containing	G	protein-
coupled	 receptors	 (LGRs),	 have	 been	 suggested	 for	 R-spondin	 interaction	 [37].	
Ohkawara	 et	 al.	 investigated	 a	 possible	 molecular	 mechanism	 for	 R-spondin	 and	
syndecan	 interaction,	 suggesting	 clathrin-mediated	 endocytosis	 of	 the	Wnt-receptor	
complex	 upon	 SDC4	 and	 R-spondin3	 binding,	 allowing	Wnt/PCP-activation	 [69].	 This	
ligand-receptor	internalisation	is	not	only	associated	with	Wnt/PCP-signalling,	but	also	
other	Wnt-cascades.	 Heparan	 sulphate	 proteoglycans	 (HSPG),	 notably	 glypicans	 and	
syndecans,	 can	 act	 as	Wnt-Coreceptors	 and	 enhance	Wnt-signalling	 by	 binding	 both	
ligand	 and	 receptor,	 allowing	 endocytosis	 and	 enhancement	 of	 Wnt-signalling	 [37].	








that	 make	 it	 difficult	 understand	 and	 predict	 Wnt-signalling.	 To	 simplify,	 one	 can	
distinguish	between	b-Catenin	dependent	and	b-Catenin	independent	signalling,	which	
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2 Aim	of	the	present	study	
Wnt-signalling	has	been	studied	in	the	context	of	a	variety	of	cellular	processes	and	has	







monocytes	 from	 healthy	 donors	 and	 in	 vitro	 generated	 M1,	 M2,	 cDC	 and	 ercDC.	
Differential	 gene	 expression	 within	 the	 canonical	 and	 non-canonical	 Wnt-signalling	
cascades	was	selectively	investigated.		
The	 effects	 of	 altering	Wnt-signalling	 via	 inhibition	 or	 stimulation,	 on	 the	 functional	
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IL10,	 human,	 TaqMan®	 Gene	 Expression	
Assay	
Thermo	 Fisher	 Scientific,	 Waltham	
(USA)	
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IL12A,	 human,	 TaqMan®	 Gene	 Expression	
Assay	
Thermo	 Fisher	 Scientific,	 Waltham	
(USA)	
IL12B,	 human,	 TaqMan®	 Gene	 Expression	
Assay	









TNFa,	 human,	 TaqMan®	 Gene	 Expression	
Assay	





































































































For	 transcriptomic	 analysis	 in	 vitro	 and	 ex	 vivo,	myeloid	microarray	 expression	 data	











































The	 freezing	 medium	 was	 prepared	 by	 adding	 Dimethylsulfoxid	 (DMSO)	 to	 the	 cell	














Cells	 were	 counted	 using	 a	 Neubauer	 counting	 chamber.	 An	 aliquot	 of	 the	 cell	
suspension	was	taken	and	mixed	with	Trypan	Blue	in	the	required	ratio	in	order	to	stain	
dead	cells	blue.	When	preparing	whole	blood	for	PBMC	extraction,	3%	acetic	acid	was	




















inhibits	 Trypsin	 and	 its	 reaction,	 and	 the	 solution	 was	 transferred	 into	 a	 tube	 and	
centrifuged.	 The	 supernatant	 was	 then	 discarded,	 the	 pellet	 resuspended	 in	 fresh	








FicollÒ	 density	 centrifugation.	 FicollÒ	 is	 a	 hydrophilic	 polysaccharide,	 which	 is	
commonly	used	to	separate	blood	into	its	components	and	the	isolation	of	PBMCs.	The	
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case	monocytes	were	 labelled	with	CD14	Micro	beads.	 	The	CD14	 receptor,	which	 is	
strongly	expressed	on	most	monocytes	and	macrophages,	but	not	on	other	cells,	is	part	
of	 a	 LPS	 receptor	 complex,	 but	 does	 not	 transduce	 signalling	 due	 to	 its	 lack	 of	 a	
cytoplasmic	domain.	The	cell	suspension	is	separated	in	a	column,	which	is	placed	in	the	
magnetic	 field	 of	 the	 MACS	 separator.	 While	 the	 unlabelled	 cells	 pass	 through	 the	
column,	 the	CD14+	 labelled	 cells	 retain	 in	 the	 column	and	 can	 later	 be	 eluted	when	
removing	the	column	from	the	magnetic	field.		
The	 following	 steps	were	 carried	out	 on	 ice.	 The	 supernatant	 of	 the	washed	PBMCs	
isolated	 through	 Ficoll	 density	 centrifugation	was	 decanted	 and	 the	 pellets	 carefully	
resuspended	 in	 10ml	 cold	 MACS	 buffer	 and	 summed	 up	 in	 a	 50ml	 Falcon	 tube.	
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In	 order	 to	 generate	 CD209+	 CD14+	 conventional	 DC	 (cDC)	 the	 isolated	 monocytes,	




On	 day	 three	 of	 culture	 another	 5ml	Miltenyi’s	 Mo-DC	 differentiation	 medium	 was	
added	 to	 each	well.	 The	 cells	were	 then	 either	 used	 as	 immature	 cells	 on	 day	 7	 or	
maturated	 using	 the	 “Jonuleit	 cocktail”	 [72]	 on	 day	 6.	 For	maturation	 on	 day	 6,	 the	
immature	 cDC	were	 harvested	 and	 re-suspended	 in	 1ml/1	 x	 106	 AIM-V	medium/1%	
L-glutamine	 plus	 “Jonuleit	 cocktail”.	 The	 “Jonuleit	 cocktail”	 is	 a	 defined	 cocktail	 of	
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L-glutamine	 without	 RCC-26-CM	 and	 matured	 by	 adding	 “Jonuleit	 cocktail”.	 This	
variation	 allowed	 investigating	 the	 effects	 of	 stimulation	 with	 i.e.	 Wnt5a,	 without	
possible	inhibiting	factors	in	the	RCC-26-CM.		
Where	indicated,	recombinant	proteins,	such	as	Wnt5a	(250ng/ml),	sFRP5	(500ng/ml)	










no	 further	proliferation	during	 the	 co-culture,	 the	 L929-CD40L-cells	were	 inactivated	
through	Caesium-irradiation	(100Gy)	and	thereafter	cultivated	for	48h	in	a	96-well-plate	
with	a	density	of	5x104cells/100µl	 LCL-medium.	The	medium	was	 then	 removed	and	
2x104	DC/200µl	AIM-V	medium	(1%HS)	added.	As	a	control	either	L929-Cd49L-cells	or	





Lipopolysaccharide	 (LPS),	 which	 can	 be	 found	 in	 the	 membrane	 of	 gram-negative	
bacteria,	has	been	shown	to	be	able	to	induce	DC	maturation.	Upon	stimulation	with	
LPS,	 DC	 increase	 their	 Antigen	 uptake,	 migration	 ability	 and	 secretion	 of	 pro-
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inflammatory	 cytokines.	 Hence,	 LPS	 can	 be	 used	 as	 a	 good	 experimental	 set	 up	 to	
simulate	and	investigate	DC	changes	during	maturation.			
To	investigate	the	differences	between	cDC	and	ercDC	and	the	effects	of	Wnt5a,	sFRP5	
and	 sFRP1	 on	 cytokine	 levels,	 DC	 were	 differentiated	 and	 harvested	 on	 day	 6	 of	
























Upon	 maturation,	 through	 for	 example	 antigen	 uptake,	 DC	 express	 the	 chemokine	
receptor	 CCR7,	 which	 allows	 migration	 towards	 the	 chemokines	 CCL19	 and	 CCL21.	
Thereby	CCL19	and	CCL21	allow	DC	 trafficking	 towards	 lymphoid	organs	where	 they	
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well	 insert	was	 incubated	 for	 1	 hour	with	 100μl	 AIM-V/1%	 L-glutamine	 prior	 to	 the	





EDTA	 was	 added	 to	 each	 well	 and	 the	 plate	 placed	 on	 a	 horizontal	 shaker	 (200	
shakes/min)	 at	 room	 temperature	 for	 10	 min.	 Thereafter	 the	 trans-well	 insert	 was	
removed	and	20μl	AccuCheck	 counting	beads	 (960	beads/μl)	were	added	 to	 the	 cell	
suspension	 in	 the	 base	well.	 The	 suspension	 containing	migrated	 cells	 and	 counting	
beads	was	then	transferred	into	a	1.5ml	FACS	tube	and	centrifuged	for	7min	at	538g.	
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within	 the	 gap	 observed	 by	 video	 microscopy.	 The	 aqueous	 gel	 matrix	 hinders	 the	
connective	flow	of	liquid,	but	at	the	same	time	allows	diffusion	in	order	to	establish	a	
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1,6	mg/ml	Collagengel	 	 with	RPMI	
	 4,54	 µl	 H2O	
	 2,50		 µl	 10x	RPMI	
	 0,25	 µl	 200mM	L-Glutamin	
9µl	gelmedium	 0,67	 µl	 7,5%	NaHCO	
	 0,40		 µl	 1M	NaOH	
	 0,39		 µl	 HEPES	
	 0,25		 µl	 BSA	
	 	 	 		16	µl	Collagen	 	 	 Collagen	5mg/ml	
	 	 	 		25	µl	cells	 	 	 cell	suspension	
	
Experiments	were	performed	with	a	CCL19	concentration	of	1.25µg/ml.	The	obtained	







allow	 the	 detection	 of	 29000	 genes	with	 an	 average	 of	 26	 probes	 per	 gene.	 	 These	






CustomCDF	 [76]	 and	 statistical	 analysis.	 All	 these	 steps	 were	 performed	 using	 the	
MADMAX	 (Management	 and	 Analysis	 Database	 for	 Multi-platform	 microArray	
eXperiments)	platform	(https://madmax.bioinformatics.nl),	University	of	Wageningen)	
[77].	Quality	control	and	normalisation	were	performed	in	order	to	assess	sample	and	
hybridization	 quality	 and	 to	 remove	non-biological	 variation	 to	 enable	 comparability	
between	 different	 microarrays.	 The	 RMA-algorithm	 used	 for	 normalisation	 includes	
background	 correction	 through	 perfect	match	 probes,	 log2	 transformation,	 quantile	
normalization	 and	 median	 polish.	 In	 order	 to	 compare	 average	 expression	 levels	
Method	
















In	 order	 to	 isolate	 RNA,	 the	 PureLink®	 RNA	 Mini	 Kit	 was	 used	 according	 to	 the	
manufacturer	instructions.	This	kit	 includes	lysis,	homogenisation	and	isolation	of	the	













DNA	 contamination	 of	 the	 sample,	 a	 RT-	 sample	was	 used	 as	 negative	 control.	 This	
Method	







































primer	 and	 probe	 are	 bounded	 and	 the	 Taq-polymerase	 amplifies	 the	 strand,	 the	
Method	
	 	 	 40	




stranded	 cDNA.	 Through	 amplification	 of	 the	 cDNA	 product	 with	 each	 cycle,	 the	
intercalated	SYBRgreen	 increases	and	hence	 increases	 the	 fluorescent	 signal	emitted	







































Endogenous	 biotin	 was	 blocked	 using	 the	 Avidin/Biotin	 Blocking	 kit.	 The	 primary	

















****	 (p	 <	 0.0001)	 and	 ns	 for	 non-significant.	 Tests	were	 utilised	 as	 indicated	 in	 the	
Method	





	 	 	 43	
5 Results	
5.1 Array-analysis	
To	 investigate	 Wnt-signalling	 in	 myeloid	 cells,	 Affymetrix	 DNA-microarrays	 were	
performed	on	peripheral	blood	monocytes	(PBMs)	and	in	vitro	generated	Macrophage1	
(M1),	Macrophage2	 (M2),	GMCSF,	 cDC	and	ercDC	 in	 the	 laboratory	of	Prof.	Nößner.	
Quality	control,	clustering	analysis	and	normalisation	were	performed	as	described	in	
methods.	 The	 DABG	 algorithm	 was	 applied	 to	 detect	 statistically	 significant	 gene	
expression	and	 fold	 changes	 (FC)	were	 calculated	 in	order	 to	 compare	average	gene	





that	 included	 canonical	 and	 non-canonical	Wnt	 genes	 (ligands,	 receptors,	 inhibitors,	
pathway	 genes	 and	 downstream	 targets).	 As	 these	 pathways	 are	 not	 yet	 fully	
understood,	the	gene	lists	do	not	include	all	genes	that	have	ever	been	associated	with	
the	 pathways,	 but	 only	 the	 most	 essential	 genes.	 The	 objective	 was	 to	 identify	 all	
relevant	genes	in	respect	to	ligands,	receptors,	co-receptors	and	downstream	effector	
proteins,	 as	well	 as	modulators	 of	 the	 signalling	 pathway	 as	 they	 relate	 to	 different	
myeloid	subtypes,	but	with	a	specific	focus	on	the	ercDC	subtype	identified	ex	vivo	from	






most	 significant	 differential	 gene	 expression	 was	 associated	 with	 the	 b-Catenin	
independent	 (non-canonical)	Wnt-pathway.	Altered	expression	within	 the	b-Catenin-
dependent	 pathway	 did	 not	 appear	 to	 affect	 the	 core-genes	 associated	 with	 this	
signalling	pathway,	but	rather	other	associated	target	genes.		
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Only	moderate	 differential	 gene	 expression	was	 detected	 for	most	 Fz-receptors,	 co-
receptors	and	no	significant	changes	were	found	for	LRP5/6.	By	contrast,	the	syndecans	
(SDC)	and	some	glypicans	(GPC)	were	strongly	regulated	in	the	activated	myeloid	cells	
(M1,	M2,	 ercDC,	 cDC)	 as	 compared	 to	 PBMs.	 Both,	 SDCs	 and	 GPCs,	 are	 part	 of	 the	
heparan	 sulphate	 proteoglycan	 family	 (HSPG)	 and	 are	 anchored	 to	 the	 cellular	













expression.	 Only	 the	 Wnt-antagonists	 IGFBP4	 and	 TraB	 domain	 containing	 2A	
(TRABD2A)	showed	strong	differential	expression.	IGFBP4,	a	canonical	Wnt-antagonist,	
is	highly	expressed	in	the	M1	macrophages	and	showed	a	FC	of	27	compared	to	all	other	





acts	 as	 a	 high	 affinity	 ligand	 for	 Fz4	 and	 LRP5/6	 and	 thereby	 activates	 b-Catenin	
dependent	 signalling	 with	 downstream	 TCF/LEF	 transcription	 factors	 [78].	 This	 Fz4	
activation	is	Wnt-ligand	independent.		
Among	 the	 Wnt-ligands,	 Wnt5a	 was	 found	 to	 be	 strikingly	 differentially	 expressed	
within	the	myeloid	populations.	It	showed	a	five-fold	increase	in	cDC	as	compared	to	all	
other	 investigated	 subsets	 of	 myeloid	 cells	 including	 the	 ercDC.	 Furthermore,	
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application	of	the	DABG-Algorithm	showed	that	Wnt5a	was	only	expressed	in	cDC,	but	
not	 in	 the	other	 investigated	myeloid	subsets.	Wnt5a	 is	a	classic	non-canonical	Wnt-
ligand.	 It	 is	able	to	bind	to	a	number	of	different	Fz-receptors	and	co-receptors	 [79].	
Canonical	Wnt-ligands,	however,	were	not	differentially	regulated.		
Differential	 gene	 expression	 within	 the	 canonical	 Wnt-pathway	 is	 summarized	 in	 a	





























of	 RHOB	 and	 a	 -6.7	 fold	 down-regulation	 of	 RAC2.	 RHOB	 was	 also	 slightly	 down-
regulated	by	two	fold	 in	cDC	and	M2.	Again,	 this	could	suggest	a	down-regulation	of	
Wnt-signalling	within	the	M1.	However,	the	regulations	of	the	PCP-cascade	are	not	as	











Fig.	 5:	 Microarray	 analysis	 of	 PCP-signalling	 pathway.	 The	 scheme	 displays	 microarray	 data	 integrated	 into	 a	
modified	version	of	 the	PCP-signalling	pathway.	Significant	differential	gene	expression	 is	presented	by	green	(up-
regulation)	or	 red	 (down-regulation)	boxes	and	 the	corresponding	 fold	changes	 in	comparison	 to	monocytes.	Fold	
changes	were	generated	using	the	RMA-Algorithm	and	a	FC	>1.5	was	considered	significant	differential	expression.	
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Within	 the	 Ca2+-signalling	 cascade	 differential	 gene	 expression	 was	 found	 for	 key	
regulating	 genes.	 Phospholipase	 C	 beta1	 (PLCB1),	 which	 forms	 inositol	














the	 Ca2+-cascade.	 The	 NLK,	 which	 is	 2.2	 fold	 up-regulated	 in	 cDC,	 phosphorylates	













regulation)	or	 red	 (down-regulation)	boxes	and	 the	corresponding	 fold	changes	 in	comparison	 to	monocytes.	Fold	
changes	were	generated	using	the	RMA-Algorithm	and	a	FC	>1.5	was	considered	significant	differential	expression.	
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Transcriptomic	analysis	identified	differential	gene	expression	within	the	Wnt-signalling	
pathway.	 While	 only	 moderate	 changes	 in	 expression	 were	 found	 within	 the	 PCP-
signalling	 cascade,	 the	differential	 expression	was	 found	 in	 the	b-Catenin-dependent	
and	the	Ca2+-cascade	pathways.	Changes	in	pathway	regulation	was	strongly	associated	
with	cDC	and	M1	myeloid	subtypes.	A	potential	reduction	in	canonical	Wnt	signalling	
with	 a	 corresponding	 increase	 in	 the	 Ca2+-signalling	 pathway	 was	 seen	 in	 cDC.	 The	
dysregulation	 in	M1	macrophages	was	difficult	 to	 assign	 to	 specific	 pathways,	 but	 it	
could	be	concluded	that	regulation	is	evident.	Interestingly,	only	few	differential	gene	
expressions	 could	be	observed	when	 comparing	 ercDC	 to	monocytes,	 suggesting	 for	
similarities	and	a	possible	explanation	for	differences	between	ercDC	and	cDC.		
Among	 the	 ligands,	 only	 Wnt5a,	 a	 non-canonical	 Wnt-activator,	 was	 strongly	 up-




As	 average	 expression	 levels	 of	 the	 different	 myeloid	 subsets	 were	 compared	 to	
monocytes,	and	all	myeloid	subsets	were	generated	from	peripheral	blood	monocytes,	
it	 becomes	 evident	 that	 Wnt-signalling	 changes	 during	 myeloid	 differentiation.	
Depending	on	the	myeloid	subset	Wnt-signalling	varies	and	canonical	or	non-canonical	
signalling	pathways	show	either	activation	or	suppression.	Hence	we	hypothesize,	that	




Wnt-signalling	 could	 in	 part	 be	 responsible	 for	 the	 functional	 differences	 and	
impairment	between	cDC	and	ercDC.		 	
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5.2 RT-PCR		
In	order	 to	validate	 the	data	obtained	by	 transcriptomic	analysis,	qPCRs	of	key	Wnt-
signalling	 genes	 were	 performed	 on	 immature	 cDC,	 ercDC	 and	 maturated	 cDC.	
Additionally,	 immature	 cDC	 and	 ercDC	 stimulated	 with	 Wnt5a	 on	 day	 zero	 of	












pathway,	 and	NFATC2,	belonging	 to	 the	Ca-Pathway,	were	both	up-regulated	 in	 cDC	
compared	 to	ercDC.	All	 other	by	qPCR	 investigated	genes	 showed	 similar	expression	
levels	between	cDC	and	ercDC	(not	shown	here).		
Furthermore,	a	tendency	of	down-regulation	in	maturated	cDC	compared	to	immature	
cDC	was	 found	 for	 several	 genes,	 including	 for	 example	Wnt5a,	 CAMK2D,	 SDC2	 and	
SDC3.	 This	 could	 suggest	 a	 possible	 change	 within	 the	 Wnt-signalling	 cascade	 and	
consequently	in	the	Wnt-response	of	cDC	during	maturation.	Addition	of	Wnt5a	on	day	
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Fig.	 7:	 Validation	 of	 gene	 expression.	 Expression	 data	 of	 Wnt-signalling	 genes	 after	 qPCR	 advanced	 relative	
quantification	analysis	of	immature	and	maturated	cDC,	ercDC	and	stimulation	with	Wnt5a(d0).	Graphs	display	ΔΔCT-
values,	mean	and	the	standard	error	of	mean	(SEM).	The	grey	bar	at	10-9	indicates	borderline	expression	and	values	
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in	 RCC.	 Immune-histological	 staining	 of	 Wnt5a	 in	 RCC	 samples	 revealed	 a	 strong	












we	 investigated	 cytokine	 gene	expression	 levels	of	 cDC	 compared	 to	ercDC,	 and	 the	
impact	of	Wnt-signalling	modulation.	We	therefore	performed	qPCRS	of	 IL-10,	TNF-α	
and	 the	 subunits	 IL12A	 (syn.	 IL12p35)	 and	 IL12B	 (syn.	 IL12p40)	of	 the	heterodimeric	
cytokine	 IL-12	(syn.	 IL12p70)	on	cDC	and	ercDC	 in	an	 immature	as	well	as	maturated	
state	 and	 upon	 stimulation	with	Wnt5a	 on	 day	 zero.	Maturation	was	 performed	 by	
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addition	of	the	“Jonuleit	cocktail”	on	day	6	of	differentiation	(see	methods).	Interestingly	
no	differences	 in	 cytokine	expression	 levels	were	 found	between	 immature	 cDC	and	
ercDC.	 Upon	 maturation,	 however,	 the	 cytokine	 expression	 levels	 of	 cDC	 changed	
significantly.	 TNF-α	 levels	were	 lowered	 significantly	 (p-value:	 0.0159)	 and	 also	 IL-10	
levels	showed	a	decreased	tendency,	but	could	not	be	shown	to	be	significant	(p-value	
0.057).	 IL12B	 levels	 of	maturated	 cDC	were	 increased	 significantly	 (p-value	 0.0159).	
Contrary	to	maturated	cDC,	maturated	ercDC	did	not	change	the	gene	expression	levels	
of	these	cytokines.	Hence,	suggesting	an	altered	response	of	ercDC	towards	maturation	







relative	 quantification	 analysis	 of	 immature	 and	maturated	 cDC,	 ercDC	 and	 stimulation	with	Wnt5a(d0).	 Graphs	
display	ΔΔCT-values,	mean	and	the	standard	error	of	mean	(SEM).	The	grey	bar	at	10-9	indicates	borderline	expression	
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5.5 Cytokine	secretion	
In	a	next	step	we	investigated	the	cytokine	secretion,	as	protein	levels,	of	cDC	compared	
to	 ercDC,	 and	 the	 impact	 of	 Wnt-signalling	 modulation	 with	 enzyme-linked	
immunosorbent-assays	 (ELISA).	 Hence	 the	 secretion	 of	 IL12p70,	 IL12p40,	 IL-10	 and	
TNF-a	 were	 measured	 upon	 LPS	 and	 CD40L	 stimulation.	 	 IL-12	 is	 a	 heterodimeric	
cytokine,	which	acts	as	a	link	between	innate	and	adaptive	immune	response.		It	is	able	
to	 induce	IFN-g	production	by	CTL	and	NK	and	activate	their	phagocytic	capacity,	but	
also	 to	 induce	 the	 generation	 of	 	 TH1	 CD4+	 cells	 [80,	 81].	 IL-10,	 however,	 acts	 as	 a	
regulator	and	suppressor	of	the	immune	system	and	can	counteract	IL-12	production	
[82].	 It	 reduces	 inflammation	 and	 prevents	 overshooting	 immune	 reactions.	
Furthermore,	it	has	been	implicated	in	CD8+	T-cell	priming	and	suggested	as	a	possible	
mechanism	for	cancers	to	escape	immune	surveillance	[83].	TNF-a	is	a	pro-inflammatory	
cytokine	 and	 involved	 in	 immune	 regulation,	 inflammation,	 cellular	 homeostasis	 and	
inhibition	of	tumourigenesis	and	viral	replication.			
A	 first	 general	 comparison	 between	 cDC	 and	 ercDC	 revealed	 that	 ercDC	 produce	
significantly	more	IL-10	and	TNF-a	when	stimulated	with	LPS	than	cDC.	This,	however,	
could	 not	 be	 shown	 for	 CD40L	 stimulation,	 as	 no	 distinctive	 results	 were	 obtained.	
Contrary,	 IL12p40	 secretion	 upon	 CD40L	 stimulation	 was	 higher	 in	 cDC	 than	 ercDC,	
although	this	could	not	be	shown	to	be	significant	by	paired	t-test.	These	differences	
between	 cDC	 and	 ercDC	 could	 in	 part	 explain	 findings	 of	 impaired	 ercDC	 ability	 to	
activate	and	induce	proliferation	of	T-cells	and	to	escape	immune	surveillance.	While	
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Following	 these	 findings,	 Wnt-signalling	 modulation	 with	 the	 non-canonical	 agonist	
Wnt5a	and	the	antagonists	sFRP1	and	sFRP5	were	performed.	Wnt5a,	sFRP1	and	sFRP5	
were	 respectively	 added	 to	 the	growth	medium	on	day	 zero	of	differentiation	 to	be	
present	throughout	the	whole	differentiation	process.		
As	Wnt5a	was	up-regulated	in	cDC	compared	to	ercDC,	it	was	expected	that	addition	of	
Wnt5a	 to	 ercDC,	 or	 blockage	 of	Wnt5a	 by	 sFRP5	 and	 sFRP1	 in	 cDC,	would	 alter	 the	
cytokine	secretion	pattern.		Yet,	addition	of	Wnt5a	did	not	show	any	significant	effects	
on	 ercDC.	 The	 obtained	 data	 was	 not	 distinct	 and	 no	 tendency	 could	 be	 detected.	
Contrary,	 however,	 Wnt5a	 showed	 significant	 effects	 regarding	 IL-10,	 TNF-a	 and	
IL12p40	secretion	in	cDC.	Addition	of	Wnt5a	to	cDC	showed	increased	secretion	levels	
of	IL-10	upon	LPS	as	well	as	CD40L	stimulation.	Increased	levels	upon	addition	of	Wnt5a	
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any	 significant	 effects	 on	 IL-10,	 IL-12	 and	 TNF-a	 secretion	 in	 cDC	 or	 ercDC.	 Unlike	
expected,	 they	 did	 not	 influence	 cytokine	 patterns	 in	 cDC,	 which	 secrete	 Wnt5a	
themselves	 or	 ercDC,	 which	 might	 be	 influenced	 through	 Wnt-signalling	 within	 the	
tumour	milieu.		
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A:	cDC+sFRP5(d0)	 	 	 	 B:	cDC+sFRP1(d0)	
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5.6 Migration	assay	









Using	 the	Boyden	chamber	migration	assay	 (MA),	we	 investigated	 the	differences	of	
migration	 ability	 of	 cDC	 as	 compared	 to	 ercDC,	 and	 the	 potential	 influence	 of	Wnt-
signalling	 modulation	 on	 the	 ability	 of	 these	 DC	 subtypes	 to	 respond	 to	 migration	
stimuli.	 It	 could	 be	 shown	 that	 cDC	migrate	 strongly	 towards	CCL19,	whereas	 ercDC	
where	 not	 attracted	 by	 this	 chemokine	 (but	 do	 express	 the	 CCR7	 receptor).	
Furthermore,	by	addition	of	CCL19	in	the	trans	well,	as	well	as	in	the	base	well,	we	could	
verify	 that	 the	 migration	 of	 cDC	 towards	 CCL19	 was	 a	 directed	 migration,	 i.e.	
chemotaxis,	and	not	chemokinesis.		
cDC	 produce	 Wnt5a,	 but	 not	 ercDC.	 However,	 as	 was	 shown	 earlier,	 RCC	 strongly	
produce	Wnt5a.	Thus,	Wnt5a	stimulation	of	ercDC	may	occur	within	the	tumour	milieu	
through	 paracrine	 signalling.	 To	 test	 the	 effect	 of	 Wnt5a	 signalling	 on	 the	 ercDC	
phenotype,	 it	was	 added	 to	 the	 cells	 on	 day	 5,	 just	 before	 onset	 of	 the	maturation	






medium	 on	 day	 3.	 Again	 no	 significant	 effect	 could	 be	 detected	 with	 the	 Boyden	
chamber	MA.		
Results	
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cDCm	did	migrate	 strongly	 towards	 CCL19,	 they	 did	 not	migrate	 towards	 fMLP.	 The	
y-FMI	was	only	 slightly	higher	upon	 fMLP	stimulation	 than	unstimulated	and	did	not	
reach	the	level	of	stimulation	with	CCL19.	The	center	of	mass	was	only	slightly	shifted	
along	 the	 y-axis.	 Accumulated	 and	 euclidean	 distance	 as	 well	 as	 velocity	 of	 fMLP	
stimulation	 were	 similar	 to	 CCL19	 stimulation.	 Interestingly,	 ercDCm	 did	 migrate	








Fig.	 16:	 µ-Slide	 Chemotaxis3D.	 Chemotactic	 response	 of	 ercDCm	 (A)	 and	 cDCm	 (B)	 towards	 CCL19	 and	 fMLP	
respectively.	While	 ercDCm	 show	no	 chemotactic	 and	 chemokinetic	 response	 towards	CCL19,	 they	 show	a	 strong	
response	 towards	 fMLP.	 Contrary,	 cDCm	 do	 not	 respond	 towards	 fMLP,	 but	 only	 towards	 CCL19	 with	 directed	
migration.	This	suggests	that	ercDCm	retain	the	immature	response	of	DC	towards	CCL19,	and	do	not	have	overall	
impaired	migration	abilities.	Furthermore,	it	can	be	noted,	that	cDCm	are	more	chemokinetic	active	than	ercDCm.		
In	a	next	 step,	we	sought	 to	determine	whether	 immature	cDC	are	 less	mobile	 than	
mature	cDC,	or	generally	more	mobile	than	immature	ercDC,	and	whether	treatment	
with	 Wnt5a	 could	 influence	 this	 mobility.	 For	 this	 experimental	 setup,	 µ-Slide	
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Chemotaxis3D	MAs	were	performed	with	 cells	 from	 the	 same	donor,	 in	an	 immature	
state	 and	 after	 maturation.	 As	 expected,	 immature	 cDC	 were	 not	 able	 to	 migrate	
towards	CCL19,	and	they	only	gained	the	ability	of	directional	migration	towards	CCL19	
through	maturation.	Wnt5a	 stimulation	 showed	 no	 significant	 effect	 on	 the	 general	
mobility	of	immature	cDC.	Velocity	and	accumulated	distance	were	slightly	decreased	
in	 immature	 cDC	 stimulated	 with	 Wnt5a	 (d0)	 compared	 to	 immature	 cDC	 without	
Wnt5a.	In	their	immature	state	cDC	behaved	similarly	to	immature	ercDC,	which	even	
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Fig.	18:	µ-Slide	Chemotaxis3D.	Chemotactic	response	of	maturated	cDC	(A)	and	ercDC	(B)	towards	CCL19.	Cells	were	
derived	 from	 the	 same	 donor	 at	 the	 same	 time	 as	 experiment	 Fig.	 12.	While	maturation	 of	 cDC	 enabled	 strong	
directional	migration	towards	CCL19,	no	directional	migration	could	be	observed	for	maturated	ercDC.		
5.8.1 Migratory	effect	of	Wnt5a,	sFRP5	and	sFRP1	on	cDC		




Thereafter	 µ-Slide	 Chemotaxis3D	 MAs	 towards	 CCL19	 was	 performed	 and	 the	 FMI,	
directionality,	 distances	 and	 velocity	 evaluated.	 As	 a	 negative	 control,	 cDCm	
medium-medium	migration	was	performed	with	each	experimental	setup.	For	statistical	
purposes,	 the	 results	of	 several	experiments,	with	different	donors	were	pooled	and	
statistical	significance	determined	using	the	Mann-Whitney	U-test	for	two-tailed	data	
and	cDCm	as	a	reference	group.	Even	though	donor	specific	differences	were	observed	
in	 these	 experiments,	 histogram	 analysis	 (by	 Kolmogorov-Smirnov-Test)	 confirmed	
Gaussian-distribution	of	pooled	data,	justifying	their	further	analysis.	
	
As	 we	 previously	 showed	 that	 cDC,	 but	 not	 ercDC,	 produce	Wnt5a,	 we	 expected	 a	
positive	 effect	 of	 Wnt5a	 and	 a	 possible	 negative	 effect	 of	 Wnt5a-inhibition	 on	 the	
migratory	behaviour	of	cDCm.	Unexpectedly	however,	Wnt5a	significantly	reduced	the	
y-FMI,	directionality,	distances	and	the	velocity.	Stimulated	with	Wnt5a,	cDCm	showed	
reduced	 motility	 and	 directed	 migration	 towards	 CCL19.	 Furthermore,	 attempted	
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inhibition	of	Wnt5a	with	sFRP5	and	sFRP1	did	not	counteract	the	effects	of	Wnt5a,	but	
also	showed	an	inhibitory	effect	on	migration,	with	reduced	FMI,	directionality,	distance	
and	 velocity.	 The	 simultaneous	 stimulation	 with	 Wnt5a	 and	 sFRP1	 also	 inhibited	
migration,	although	this	effect	was	not	additive.	Overall	 it	could	be	shown	that	Wnt-
signalling	 modification	 seemed	 to	 inhibit	 the	 migration	 of	 cDCm	 in	 all	 investigated	
























































































































































several	 experiments	were	 pooled	 and	 the	Mann-Whitney	U-test	 for	 two-tailed	 data,	
with	 ercDCm	 as	 reference	 group,	 applied	 in	 order	 to	 test	 for	 statistical	 significance.		






were	added	on	day	0	of	 differentiation.	 For	 statistical	 analysis	 the	Mann-Whitney	U-test	 for	 two-tailed	data	was	
applied	and	cDC	used	as	a	reference	group.		













































































































	 	 	 67	
5.9 Microarray	analysis	of	ex	vivo	cDC	and	ercDC	
All	initial	experiments	were	performed	with	in	vitro	generated	PBMC	derived	cDC,	ercDC	





slanDC	 (CD11c+,	 slan+,	 CD19-)	were	 obtained	 from	blood	 samples	 of	 healthy	 donors.	










of	 the	 Wnt-ligands	 or	 receptors	 and	 only	 little	 for	 co-receptors,	 agonists	 and	






canonical	 as	 well	 as	 non-canonical	 signalling	 was	 evident	 and	 suggest	 possible	
mechanism	for	impaired	ercDC	functioning.		
Results	







red	 (down-regulation)	boxes	and	 the	corresponding	 fold	changes	 in	comparison	 to	monocytes.	Fold	changes	were	
generated	using	the	RMA-Algorithm	and	a	FC	>1.5	and	<-1.5	was	considered	significant	differential	expression.	
Results	





canonical	 (A),	 Ca2+	 (B)	 and	PCP	(C)	Wnt	pathway.	 FC	were	 calculated	 comparing	 slanDC	 (CD11c+,	 slan+,	 CD19-)	 to	
ercDC_RCC	(CD209+CD14+CD163+).	Significant	differential	gene	expression	is	presented	by	green	(up-regulation)	or	red	
(down-regulation)	 boxes	 and	 the	 corresponding	 fold	 changes	 in	 comparison	 to	 monocytes.	 Fold	 changes	 were	
generated	using	the	RMA-Algorithm	and	a	FC	>1.5	and	<-1.5	was	considered	significant	differential	expression.	
Results	






































infiltrated	 by	 leukocytes.	 However,	 a	 negative	 correlation	 of	 increased	mononuclear	
cells	in	the	infiltrate	with	prognosis	has	been	observed,	suggesting	that	the	immune	cells	
do	not	properly	function	in	their	role	as	anti-tumour	defence	[87].	Recent	studies	have	
attempted	 to	 investigate	 the	 composition	 of	 this	 infiltrate	with	 special	 emphasis	 on	
subtype	 identification	and	 functionality.	A	deeper	understanding	of	RCC	 immunology	
and	the	factors	involved	in	tumour	escape	from	an	eliminating	immune	response,	could	
reveal	 prognostic	 factors	 and	 identify	 new	 therapeutic	 approaches.	 Schleypen	 et	 al.	
investigated	the	influence	of	cytotoxic	marker	expression	and	the	frequency	of	natural	




disease	 progression.	 The	 granulocyte/DC	 ratio,	 for	 example,	 was	 proposed	 as	 a	
biomarker	 for	 immune	monitoring	 of	 RCC	 patients	 [89].	 SlanDC,	 a	 proinflammatory	
subset	of	myeloid	DC,	have	been	shown	 to	accumulate	 in	primary	ccRCC,	metastatic	
lymph	nodes	and	metastases	[90].	These	RCC	infiltrating	slanDC,	however,	differ	from	
slanDC	 found	 in	healthy	human	blood,	 as	 they	present	 an	 immature	phenotype	 and	
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that	ercDC	resemble	DC	as	well	as	Mf,	but	based	on	gene	expression	analysis,	appear	
to	show	more	similarities	to	Mf,	especially	to	an	inflammatory	Mf	subtype	found	within	
the	 ascites	 produced	 by	 ovarian	 cancer.	 ErcDC	 can	 be	 generated	 in	 vitro	 through	
addition	 of	 CXCL8/IL-8,	 IL-6	 and	 VEGF,	 which	 are	 highly	 expressed	 by	 RCC	 [91].	
Furthermore,	D.	Brech	has	shown	that	PGE2,	glucocorticoids	(GC)	and	palmitic	acid	(PA),	
or	a	 combination	of	TNF,	PGE2	and	Pam3CysSerLys4	 found	within	 the	 tumour	milieu	
influence	 the	 differentiation	 of	 ercDC	 and	 thus	 could	 explain	 the	 proangiogenic	 and	
invasive	gene	expression	of	ercDC,	which	promote	tumour	progression.	Moreover,	she	
identified	 signs	of	 tolerogenic	 and	protumoural	 characteristics,	 such	 as	 the	 impaired	
ability	of	ercDC	to	induce	T-cell	proliferation.		
In	the	present	work,	my	goal	was	to	further	identify	differences	between	ercDC	and	cDC.	
As	 cytokine	 production	 plays	 a	 pivotal	 role	 in	 influencing	 cell	 signalling,	 immune	




from	 an	 immune	 response	 [83].	 Recent	 studies	 reported	 a	 low,	 chronic	 secretion	 of	
TNF-a	 in	RCC	and	showed	that	this	correlates	with	poor	prognosis	[84].	In	support	of	
these	findings,	my	work	could	show	that	ercDC	produce	significantly	more	TNF-a	and	








and	 prime	 T-cells	 for	 a	 directed,	 adaptive	 immune	 response.	 While	 cDC	 migrated	
strongly	 towards	 CCL19,	 ercDC	 did	 not	 respond	 to	 CCL19	 stimulation	 although	 they	
express	 the	 receptor	 CCR7.	 To	 ensure	 that	 ercDC	 have	 the	 ability	 to	migrate,	 ercDC	
migration	towards	fMLP	was	tested.	fMLP	is	a	cleavage	product	of	bacteria	and	attracts	
leukocytes	 to	 the	 site	of	 inflammation.	 FPR,	 the	 receptor	 for	 fMLP,	was	 found	 to	be	
Discussion	


















While	 Wnt-signalling,	 especially	 β-catenin	 dependent	 signalling,	 has	 been	 studied	
extensively	 in	other	cancers,	such	as	colorectal	cancer,	breast	cancer	and	melanoma,	
only	 little	 is	 known	 about	 its	 involvement	 in	 RCC.	 Controversial	 results	 of	 β-Catenin	
expression	levels	have	been	detected,	yet	all	of	these	studies	confirm	the	importance	of	
β-Catenin-signalling	 in	 RCC.	Multilayer-omics	 	 studies	 identified	 gene	mutations	 and	
epigenetic	 as	 well	 as	 mRNA	 expression	 alterations	 of	 canonical	 Wnt-signalling	 in	
RCC	[92].	 Increased	 expression	 levels	 of	Wnt	 receptors	 Fzd5,	 7	 and	 8	 [93]	 and	Wnt-
ligands,	 such	 as	Wnt1	 and	Wnt10A	 could	 be	 detected	 [94].	 Furthermore,	 decreased	
expression	levels	were	detected	for	extracellular	Wnt-antagonists,	such	as	DKK,	IGFBP4	





to	 further	 elucidate	 its	 potential	 involvement.	 Immunohistochemistry	 demonstrated	
Discussion	




Although,	 Shiina	 et	 al.	 and	 Kruck	 et	 al.	 detected	 increased	 levels	 of	 canonical	 Fzd-
receptors	and	Wnt-ligands,	these	findings	could	not	be	verified	in	our	gene	array	analysis	
performed	on	RCC	samples.	In	addition,	no	differential	expression	of	β-Catenin	and	only	
slight	 variations	 in	 other	 genes	 linked	 to	 canonical	 Wnt	 signalling	 were	 observed.	
Possible	 reasons	 for	 these	 deviations	 from	 the	 published	 literature	 include	 differing	














Interesting	was	 the	 differential	 expression	 of	 HSPG,	 and	 especially	 the	 strong	 down	
regulation	of	glypicans	3	and	5	found	in	RCC	as	compared	to	healthy	kidney.	Glypicans	
are	 HSPGs	 that	 are	 covalently	 bound	 to	 the	 plasma	 membrane	 through	 a	
glycosylphosphatidylinositol	 anchor.	 They	 can	 regulate	 signalling	 pathways	 through	
ligand-receptor	interaction	and	thereby	exhibit	inhibitory	as	well	as	stimulatory	effects.	
Similarly	to	Wnt5a,	GPC3	is	up-regulated	during	development,	but	down	regulated	in	
most	 adult	 tissues,	with	 the	 exception	 of	mesothelium,	 breast	 and	 ovarian	 epithelia	
[100].	GPC3	up-regulation	was	detected	in	hepatocellular	carcinoma	(HCC)	and	has	been	
shown	 to	 promote	 β-Catenin	 dependent	 signalling	 through	 direct	 ligand	 receptor	
interaction,	e.g.	with	Wnt3a	and	Fzd8,	and	increased	ligand	concentration	at	the	cellular	
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membrane	[101].	Furthermore,	 it	was	shown	to	be	involved	in	cellular	migration	and	
motility	 in	HCC	 [102].	GPC3	has	 been	 shown	 to	have	 inhibitory	 effects	 on	β-Catenin	
dependent	signalling,	and	promote	activation	of	non-canoncial	PCP	signalling	in	breast	
cancer.	 In	this	context,	 it	 is	thought	to	promote	mesenchymal-epithelial	transmission	
(MET),	 and	 thereby	 inhibit	metastasis	 and	 the	 invasiveness	 of	 tumours	 [100].	 These	
contrary	effects	of	GPC3	on	Wnt-signalling	could	be	explained	in	part	by	cellular	context,	
as	well	as	the	ligands	and	receptors	involved.	Castillo	et	al.	have	suggested	that	GPC3	
expression	 patterns	 depend	 on	 the	 tumour	 tissue	 and	 its	 origin.	 GPC5	 shows	 high	
homology	to	GPC3.	However,	only	little	is	known	about	its	exact	role.	It	has	been	shown	








contrary	 results	 and	 functions	 were	 described	 for	 the	 same	 gene.	 These	 results	
underscore	 the	 diversity	 and	 complexity	 of	 Wnt-signalling	 in	 tumour	 biology.	 The	
activation	of	these	pathways	depend	on	the	intricate	interplay	of	ligands,	receptors,	co-
receptors	 and	 down-stream	 signalling	 pathways.	 The	 detection	 of	mRNA	 expression	







The	major	goal	of	 this	 thesis	was	 to	 study	 the	potential	 role	of	Wnt-signalling	 in	 the	




	 	 	 76	
myeloid	 cells	 and	 thereby	 promote	 RCC	 growth.	 Transcriptomic	 analysis	 of	 in	 vitro	
generated	monocyte	derived	DC	and	Mf	was	used	to	identify	potential	differences	in	














thought	 to	 be	 essential	 for	 Wnt5a	 autocrine	 signalling,	 internalization	 and	 signal	
transduction,	especially	in	non-canonical	signalling	of	melanoma	cells	[105].	GPC4	has	
recently	 been	 shown	 to	 inhibit	 β-Catenin	 signalling	 in	 cardiomyocytes	 by	 possibly	







signalling	 pathways	 were	 seen	 between	 the	 myeloid	 subsets.	 Activation,	 as	 well	 as	
suppression	of	canonical	and	non-canonical	signalling	was	observed	depending	on	the	
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and	Mf,	 has	 been	 previously	 shown	 by	 others	 [108].	 Furthermore,	Wnt5a	 addition	





the	 cellular	 and	 tissue	 context.	 Wnt5a	 secretion	 by	 melanoma	 cells,	 for	 example,	
influences	 DC	 to	 induce	 Treg	 development	 via	 β-Catenin	 dependent	
indoleamine	2,3-dioxygenase-1	 activation	 [111],	 highlighting	 that	Wnt5a	 can	 activate	
canonical	 as	 well	 as	 non-canonical	 signalling	 in	 a	 cell	 and	 receptor	 specific	manner.	
Activation	 of	 β-Catenin	 dependent	 signalling	 through	 Wnt5a	 promotes	 DC	 with	
tolerogenic	features,	so	called	semi-maturate	DC	[112].	Valencia	et	al.	describe	Wnt5a	
signalling	 in	 DC,	 but	 distinguish	 between	 effects	 of	 Wnt5a	 stimulation	 during	 DC	
differentiation,	maturation	and	function.	This	emphasises	the	assumption	that	Wnt5a	
signalling	 is	 complex,	 and	 its	 effects	 may	 differ	 depending	 on	 different	 cellular	
conditions.	 They	 show	 that	 non-canonical	Wnt5a	 signalling	 skews	 the	 cells	 toward	 a	














subtypes,	 specifically	 on	 the	 ercDC	 subtype	 associated	 with	 RCC.	 Although	 we	
hypothesized	 that	Wnt5a	may	 enhance	 the	migratory	 ability	 of	 cDC,	 we	 found	 that	
Wnt5a	addition	during	differentiation	of	peripheral	blood	monocyte	derived	cDC	had	
the	 opposite	 effect,	 leading	 to	 reduced	 motility,	 velocity	 and	 directed	 migration.	








Similarly,	Wnt5a	 did	 not	 exert	 any	 effects	 on	 cytokine	 secretion	 of	 ercDC.	However,	
addition	of	Wnt5a	to	cDC	resulted	in	increased	IL-10,		IL12p40,	IL12p70,	but	decreased	
TNF-a	levels.	While	the	high	secretion	of	IL-10	upon	Wnt5a	stimulation	resembled	the	
high	 secretion	 of	 unstimulated	 ercDC,	 the	 effects	 on	 TNF-a	 and	 IL-12	 were	 rather	
contrary.	Hence,	addition	of	Wnt5a	can	only	 in	part	explain	the	 impaired	functioning	
and	altered	phenotype	of	ercDC.	Interestingly,	immature	cDC	and	ercDC	did	not	show	









Contrary	to	what	was	expected,	 the	addition	of	 the	Wnt	 inhibitors	sFRP5	and	sFRP1,	
showed	a	similar	effect	to	that	seen	with	Wnt5a.	These	factors	have	been	previously	
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reported	to	 inhibit	Wnt5a	signalling.	 In	 the	context	of	 this	experiment,	however,	 the	
agents	appear	to	act	as	agonists.	sFRPs	exert	their	function	via	a	similar	CRD	as	the	Wnt-


























differentiation	 medium	 provided	 by	 Miltenyi	 Biotec.	 This	 medium	 contains	 FBS,	
RPMI	1640,	 L-Glutamine,	 GM-CSF	 and	 IL-4	 and	 allows	 a	 lot-to-lot	 consistent	
standardized	 protocol	 for	 DC	 differentiation.	 However,	 even	 though	 this	 protocol	 is	
often	 used,	 the	 relevance	 of	monocytes	 as	 in	 vivo	 precursors	 of	 DC	 is	 not	 yet	 fully	
Discussion	







on	 in	 vitro	 generated	DC	 should	be	made	 carefully,	 especially	when	 transferring	 the	
acquired	knowledge	to	biology	of	in	vivo	DC.		
In	order	to	validate	our	transcriptomic	analysis	data	based	on	in	vitro	generated	cDC	and	
ercDC,	we	 compared	 the	 obtained	 results	with	 recent	 array	 data	 from	 ex	 vivo,	 RCC	
derived	cDC	and	ercDC.	While	strong	differential	gene	expression	between	ex	vivo	cDC	
and	ercDC	regarding	canonical	and	non-canonical	Wnt-signalling	was	evident,	it	did	not	









DC	are	and	whether	 results	based	upon	 in	vitro	 studies	 can	be	 transferred	 to	better	
understand	 the	 complex	 in	 vivo	 DC	 biology.	 Royer	 et	 al.	 investigated	 the	 effect	 of	
differing	culture	media	and	adjuvant	proteins	on	DC	phenotype	and	immune	capacity.	
They	could	show	that	depending	on	culture	medium	and	supplements,	e.g.	HSA	or	FCS,	















functioning	 in	 the	 tumour	milieu	of	RCC	and	suggest	a	possible	 role	of	Wnt5a	 in	 the	
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Wnt	1	 7471	 1.0478	 1.1137	 -1.0599	 -1.0485	 1.0120	
Wnt	2	 7472	 -1.1159	 -1.1643	 1.0786	 -1.0346	 -1.1793	
Wnt	2b	 7482	 1.2493	 1.3829	 1.8945	 1.6519	 1.5486	
Wnt3	 7473	 -1.0657	 -1.0621	 -1.2824	 -1.1541	 -1.0118	
Wnt	3a	 89780	 -1.0484	 1.0263	 -1.1117	 -1.0742	 1.0057	
Wnt	4	 54361	 -1.0149	 -1.0366	 1.0241	 1.0444	 1.0382	
Wnt	5a	 7474	 5.0499	 1.3656	 1.2981	 -1.0402	 -1.0651	
Wnt	5b	 81029	 1.2944	 1.1507	 -1.0462	 -1.1872	 -1.0099	
Wnt	6	 7475	 -1.0217	 -1.0908	 1.0183	 1.0577	 1.0700	
Wnt	7a	 7476	 -1.0942	 -1.1713	 1.0001	 -1.1834	 -1.0997	
Wnt	7b	 7477	 -1.1037	 1.0378	 -1.0600	 -1.0944	 -1.1809	
Wnt	8a	 7478	 1.0791	 1.2026	 1.0383	 1.1184	 1.0286	
Wnt	8b	 7479	 -1.1196	 -1.2019	 -1.1273	 -1.1105	 -1.1273	
Wnt	9a	 7483	 -1.0643	 -1.0670	 -1.0760	 1.0467	 -1.0709	
Wnt	9b	 7484	 -1.0681	 1.0270	 -1.1525	 -1.0818	 -1.0741	
Wnt	10a	 80326	 -1.1058	 1.0172	 -1.0888	 -1.0502	 1.0937	
Wnt	10b	 7480	 -1.1798	 -1.1405	 1.0292	 -1.2164	 -1.0193	
Wnt	11	 7481	 1.0567	 1.0421	 -1.0120	 1.0235	 -1.0042	
Receptors	
Fzd1	 8321	 -1.1940	 -1.0202	 1.1876	 -1.5238	 1.0084	
Fzd2	 2535	 1.0362	 -1.1441	 -1.1968	 -1.2572	 -1.1570	
Fzd3	 7976	 1.6825	 1.2213	 -1.0577	 -1.0286	 -1.0129	
Fzd4	 8322	 -1.0758	 -1.1363	 1.0001	 -1.0596	 1.0678	
Fzd5	 7855	 1.6328	 1.6570	 2.3540	 1.3563	 1.5308	
fzd6	 8323	 -1.1244	 -1.0507	 1.1862	 -1.1625	 1.0726	
Fzd7	 8324	 1.2094	 1.1684	 -1.0433	 1.6801	 1.0872	
Fzd8	 8325	 -1.1847	 -1.0675	 1.1257	 -1.1052	 -1.0865	
Fzd9	 8326	 -1.1324	 -1.0036	 -1.1307	 -1.2065	 -1.1476	
Fzd10	 11211	 -1.0362	 -1.0641	 -1.1107	 -1.0839	 -1.0057	
Co-receptors	
LRP5	 4041	 1.0425	 1.0545	 1.0456	 -1.1117	 -1.0982	
LRP6	 4040	 1.0442	 -1.1025	 1.2047	 -1.0164	 -1.1069	
LRP1	 4035	 1.0983	 1.1279	 -4.4389	 1.2263	 1.1907	
Kremen	1	 83999	 -1.0562	 -1.2954	 1.3496	 1.1663	 -1.1561	
Kremen	2	 79412	 -1.1588	 -1.0619	 -1.1339	 -1.2653	 -1.0823	
RYK	 6259	 1.5829	 1.1947	 1.0334	 1.2196	 1.0210	
ROR1	 4919	 1.2579	 1.1067	 -1.0999	 1.0407	 1.1640	
ROR2	 4920	 1.0097	 1.0564	 1.1123	 1.0182	 1.1341	
VANGL1	 81839	 -1.0065	 -1.0374	 -1.0785	 1.0427	 1.0967	
VANGL2	 57216	 -1.1272	 -1.1182	 -1.1037	 -1.0352	 -1.0528	
CELSR1	 9620	 1.3749	 1.6053	 1.0304	 1.6621	 1.8117	
CELSR2	 1952	 -1.0571	 -1.1768	 -1.3285	 -1.2005	 -1.1994	
CELSR3	 1951	 -1.0029	 -1.0239	 -1.0833	 1.0057	 1.0126	
PTK7	 5754	 -1.1457	 -1.0947	 -1.0110	 -1.0483	 -1.0982	
SDC1	 6382	 -1.1248	 -1.0977	 1.0042	 1.0102	 -1.0464	
SDC2	 6383	 26.8547	 25.5374	 6.6457	 17.9097	 9.5164	
SDC3	 9672	 2.3762	 2.6069	 1.4328	 1.4247	 2.7031	
SDC4	 6385	 6.4081	 10.8838	 11.2835	 9.3504	 7.7408	
GPC2	 221914	 -1.1221	 -1.0885	 -1.0545	 -1.0461	 -1.1324	
GPC3	 2719	 -1.0980	 -1.0464	 1.1636	 1.0768	 -1.0608	
GPC4	 2239	 5.7710	 4.9093	 8.9275	 7.3588	 6.9322	
GPC5	 2262	 1.0140	 1.0747	 1.5207	 1.1036	 1.1229	
GPC6	 10082	 -1.1176	 -1.1559	 -1.1314	 -1.0030	 -1.1989	
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GPC1	 2817	 -1.0188	 -1.0845	 -1.3223	 -1.0810	 -1.1129	
CD44	 960	 1.1727	 1.0178	 1.2675	 1.2640	 -1.1106	
Inhibitors	
Dkk1	 22943	 -1.2269	 -1.1954	 -1.1426	 -1.0695	 -1.2161	
Dkk2	 27123	 -1.1293	 1.4759	 -1.0151	 -1.0348	 -1.1505	
Dkk3	 27122	 -1.1490	 -1.1092	 1.0491	 -1.0099	 -1.0352	
Dkk4	 27121	 -1.0170	 -1.1018	 1.1006	 1.0211	 -1.0639	
WIF1	 11197	 -1.1668	 -1.0380	 1.0095	 1.0290	 -1.0021	
sFRP1	 6422	 -1.1427	 -1.0632	 1.0010	 1.0126	 -1.2376	
sFRP2	 6423	 -1.0946	 1.0135	 -1.1346	 1.0345	 -1.0707	
sFRP3	 2487	 -1.1410	 -1.1193	 1.0137	 1.0502	 -1.1478	
sFRP4	 6424	 1.1390	 1.2671	 1.0846	 1.0664	 1.1427	
sFRP5	 6425	 1.0184	 -1.0106	 -1.0684	 -1.0486	 1.0179	
Shisa2	 387914	 -1.3154	 -1.1454	 -1.3957	 -1.2841	 -1.2513	
Shisa3	 152573	 1.0578	 1.0007	 1.2062	 -1.0021	 1.1512	
CTHRC1	 115908	 -1.0945	 -1.1229	 1.0315	 -1.1654	 1.0169	
IGFBP1	 3484	 -1.1135	 -1.0935	 1.1107	 -1.0644	 1.0712	
IGFBP2	 3485	 2.0006	 1.2833	 1.0485	 2.5624	 1.1074	
IGFBP4	 3487	 1.0751	 1.2708	 27.7678	 -1.0669	 1.4595	
IGFBP6	 3489	 1.2435	 -1.0573	 1.0969	 -1.0126	 1.0371	
CER1	 9350	 -1.2912	 -1.1755	 1.0267	 1.0636	 -1.1883	
SOST	 50964	 -1.1291	 -1.0781	 -1.1195	 -1.1004	 -1.1172	
SOSTDC1	 25928	 -1.1406	 -1.2441	 -1.0490	 -1.1310	 -1.0812	
TPBG		 7162	 -1.1712	 -1.0196	 -1.0649	 1.0571	 1.0392	
APCDD1	 147495	 -1.7306	 -1.8358	 -1.6678	 -2.0023	 -1.9006	
TRABD2A		 129293	 3.7015	 -1.0753	 -1.0146	 1.4683	 1.0429	
agonists/	positive	modulators	
NDP	 4693	 2.6809	 1.1334	 1.6308	 1.3193	 1.1137	
RSPO1	 284654	 -1.0356	 1.0406	 1.0656	 -1.0297	 -1.0627	
RSPO2	 340419	 -1.0377	 -1.0174	 -1.1584	 -1.1436	 -1.0729	
RSPO3	 84870	 -1.2312	 -1.0773	 -1.0881	 1.0941	 -1.0633	
RSPO4	 343637	 -1.2118	 -1.2918	 -1.2725	 -1.1669	 -1.2664	
ß-Catenin	dependent	signalling	
Dvl1	 1855	 -1.0077	 -1.0212	 -1.1000	 -1.0158	 -1.0566	
Dvl2	 1856	 1.1384	 1.1115	 1.0360	 1.4196	 1.2250	
Dvl3	 1857	 1.0678	 1.0474	 1.2670	 1.0842	 1.1509	
GSK3ß	 2932	 -1.1435	 -1.2545	 -1.0061	 -1.0254	 -1.0594	
Axin	1	 8312	 -1.0020	 1.1640	 1.0146	 1.1054	 -1.1066	
Axin	2	 8313	 -1.1370	 1.0114	 -1.1245	 1.0421	 -1.1323	
APC	 324	 -1.0674	 -1.4986	 -1.2794	 -1.0184	 -1.1618	
CSNK1A1	 1452	 -1.0028	 -1.0073	 -1.2442	 -1.1706	 -1.2162	
CSNK1E	 1454	 1.8168	 2.2686	 -1.0147	 1.9968	 1.4481	
CSNK1D	 1453	 -1.3106	 -1.1585	 -1.1473	 -1.0886	 -1.2703	
CSNK2A1	 1457	 1.7151	 1.4747	 1.1542	 1.4473	 -1.0620	
CSNK2A2	 1459	 1.3787	 1.4801	 1.1321	 1.5653	 1.1586	
CSNK2B	 1460	 1.5749	 1.5673	 -1.1649	 1.2529	 1.0740	
CTNNB1	 1499	 1.0325	 1.3101	 2.1273	 -1.0417	 1.1365	
CTNNBIP1	 56998	 -1.2974	 -1.2827	 -1.4591	 -1.3467	 -1.0918	
NDRG1	 10397	 1.2263	 -1.0287	 1.0248	 2.3875	 1.3126	
NDRG2	 57447	 3.2720	 -1.2540	 -1.4075	 1.2947	 -1.3170	
FRAT1	 10023	 -2.0934	 -4.2753	 -4.8864	 -1.9421	 -2.5590	
FRAT2	 23401	 -1.0051	 -1.8382	 -2.4926	 1.0518	 -1.5536	
PAK4	 10298	 -1.0559	 -1.0419	 1.0545	 -1.0362	 -1.0467	
AKT1	 207	 1.0727	 1.0076	 -1.2579	 -1.2273	 1.0050	
AKT2	 208	 -1.0234	 -1.0023	 1.2957	 -1.0031	 -1.0020	
AKT3	 10000	 -1.0556	 1.2061	 2.7455	 2.1395	 1.7693	
ILK	 3611	 -1.3309	 -1.2260	 1.1650	 -1.4029	 -1.0632	
CXXC4	 80319	 -1.0795	 -1.0460	 -1.1647	 -1.0098	 -1.1332	
SUMO1	 7341	 1.2422	 1.0634	 1.0334	 -1.0801	 1.0897	
RANBP2	 5903	 1.1914	 1.4217	 -1.0105	 1.0314	 -1.0073	
SENP2	 59343	 -1.2144	 -1.3138	 -1.0094	 1.0007	 -1.4116	
BTRC	 8945	 1.5230	 1.1182	 1.0634	 1.3534	 1.0955	
SKP1	 6500	 1.0463	 -1.1129	 -1.0360	 1.0865	 -1.1832	
CUL1	 8454	 1.0682	 1.1666	 3.5811	 1.2519	 -1.2846	
NKD1	 85407	 -1.0889	 -1.0214	 1.1297	 -1.0088	 -1.0119	
ARRB1	 408	 -1.5309	 -1.5627	 -1.0906	 -1.6392	 -1.2186	
ARRB2	 409	 -1.8236	 -1.3505	 -1.9410	 -1.7086	 -1.2804	
MACF1	 23499	 1.0032	 1.4368	 3.1303	 -1.4268	 1.4177	
PPP1CA	 5499	 -1.0971	 -1.2032	 -1.6766	 -1.2980	 -1.0472	
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PPP1CB	 5500	 -1.3857	 -1.2836	 -1.1046	 -1.4058	 -1.4033	
PPP1CC	 5501	 1.0556	 -1.0985	 -1.5390	 1.2284	 -1.0003	
PPP2R5B	 5526	 -1.4492	 -1.5188	 1.0017	 -1.2962	 -1.2832	
PPP2CB	 5516	 1.1577	 1.4632	 1.9676	 1.2064	 1.3461	
PPP2CA	 5515	 -1.3256	 -1.1105	 -1.1280	 -1.3437	 -1.3523	
PPP3CB	 5532	 -1.1929	 -1.1702	 -1.2772	 -1.0798	 -1.0620	
DAB2	 1601	 6.8342	 8.9126	 3.3473	 8.9411	 11.2741	
TCF1	 6927	 1.0999	 1.0152	 -1.0610	 -1.0259	 1.0979	
TCF3	 6929	 1.1808	 1.2276	 -1.3194	 1.0366	 1.0088	
TCF4	 6925	 2.0252	 2.7192	 5.1342	 -1.8166	 2.1165	
LEF1	 51176	 -1.1706	 -1.2622	 -1.1247	 -1.0747	 1.4940	
TCF7L1	 83439	 -1.1656	 -1.1750	 1.2834	 -1.0844	 -1.1102	
TCF7L2	 6934	 -5.6145	 -5.3457	 -4.0381	 1.9644	 -2.7601	
TLE1	 7088	 4.2189	 3.5446	 1.3227	 1.6946	 1.2847	
TLE2	 7089	 -1.1592	 1.0052	 -1.2013	 1.0606	 -1.0114	
TLE3	 7090	 -1.7896	 -1.2458	 -5.6279	 -1.4681	 -1.0852	
TLE4	 7091	 -1.9182	 -1.7843	 -1.8317	 -1.7156	 -2.0216	
CDX1	 1044	 -1.2265	 -1.1330	 -1.2034	 -1.1406	 -1.0821	
BCL9	 607	 1.2041	 1.1923	 -1.4637	 -1.1155	 -1.2702	
PIAS4	 51588	 -1.1180	 -1.1361	 -1.1656	 1.0687	 -1.1316	
FHL2	 2274	 -1.1385	 -1.0177	 -1.0116	 -1.0242	 -1.1351	
TAX1BP3	 30851	 1.1900	 1.1222	 -1.1825	 1.0423	 1.0370	
SALL1	 6299	 -1.0629	 1.0353	 -1.1064	 -1.0805	 -1.1476	
SALL4	 57167	 -1.0078	 -1.0791	 -1.0304	 -1.0509	 -1.0910	
MAP1B	 4131	 -1.0230	 1.0534	 1.0761	 -1.0505	 1.0295	
PCP	signalling	
ANKRD6	 22881	 1.3379	 1.2828	 1.1069	 1.4564	 1.6408	
DAAM1	 23002	 2.0291	 1.2277	 -2.4222	 -1.6253	 -1.2703	
DAAM2	 23500	 -1.1115	 -1.1538	 -1.0051	 -1.0658	 -1.0630	
RHO	A	 387	 -1.0749	 -1.1261	 -1.2114	 -1.2304	 -1.1508	
RHO	B	 388	 -1.9047	 -2.0169	 -2.8387	 -1.5755	 -1.4729	
ROCK1	 6093	 -1.3520	 -1.4745	 -1.7087	 -1.3189	 -1.5281	
ROCK2	 9475	 1.2736	 1.0840	 1.0213	 1.0924	 -1.1808	
RAC1	 5879	 -1.0341	 -1.1305	 1.4357	 1.1597	 1.0920	
RAC2	 5880	 1.1084	 -1.4144	 -6.7489	 -1.0065	 -1.3686	
RAC3	 5881	 -1.0337	 -1.0597	 -1.0107	 -1.0068	 -1.1778	
MAP2K7	 5609	 -1.3565	 -1.1139	 -1.0733	 -1.0140	 -1.3529	
MAP2K4	 6416	 1.1980	 1.0955	 1.3847	 1.0420	 -1.0306	
MAP3K4	 4216	 1.0504	 -1.1367	 -1.7921	 -1.0399	 -1.3015	
MAPK8	 5599	 -1.5394	 -1.1032	 -1.2819	 -1.2300	 -1.1249	
MAPK9	 5601	 1.4818	 1.1390	 -1.1602	 1.0375	 1.1043	
MAPK10	 5602	 -1.1782	 -1.0914	 -1.0572	 -1.1085	 -1.0427	
JUN	 3725	 1.0972	 1.5890	 1.3903	 1.4314	 -1.0270	
ATF2	 1386	 1.0705	 1.1227	 1.2299	 -1.0230	 1.2329	
CDC42	 998	 -1.6011	 -1.4475	 -1.2920	 -1.3913	 -1.4254	
MARK2	 2011	 -1.5442	 -1.7883	 -1.7048	 -1.7351	 -1.8013	
Ca-Signalling	
PLCB1	 23236	 -6.1276	 -7.2183	 -8.6383	 -9.5319	 -8.8037	
PLCB2	 5330	 -1.3916	 -1.7778	 -15.9277	 -2.8603	 -1.7213	
PLCB3	 5331	 -1.2168	 1.0497	 -1.1470	 -1.2337	 -1.1461	
PLCB4	 5332	 -1.1066	 -1.1022	 1.0774	 -1.0391	 -1.0927	
PLCG1	 5335	 1.4294	 1.0326	 1.0172	 1.0453	 1.2639	
PLCG2	 5336	 -1.1341	 -1.6673	 -2.1837	 -1.4115	 -1.2078	
PLCD1	 5333	 1.4100	 1.1912	 -1.0767	 2.0738	 1.3305	
PLCD3	 113026	 -1.0531	 -1.0058	 -1.1065	 -1.0824	 -1.1213	
PLCD4	 84812	 -1.2495	 -1.0002	 -1.0473	 -1.0208	 -1.0271	
PLCE1	 51196	 1.1222	 1.1445	 1.0809	 1.1054	 1.1868	
PRKCA	 5578	 3.3514	 1.6840	 -1.6743	 1.3901	 1.8637	
PRKCB	 5579	 -3.2992	 -4.1438	 -6.1427	 -3.6640	 -1.9495	
PRKCG	 5582	 -1.1439	 -1.1418	 -1.1841	 -1.0150	 -1.0262	
CAMK1	 8536	 1.6321	 1.0665	 -3.3369	 -1.3655	 1.1039	
CAMK1D	 57118	 1.6759	 1.4681	 -3.3233	 -1.4166	 1.3677	
CAMK1G	 57172	 -1.0030	 1.0487	 3.4686	 -1.0618	 1.1956	
CAMK2A	 815	 -1.2510	 -1.3186	 -1.0654	 -1.2583	 -1.2725	
CAMK2B	 816	 -1.2008	 -1.0613	 1.0337	 -1.0812	 -1.0314	
CAMK2G		 818	 -1.5428	 -1.9162	 -2.6514	 -1.6674	 -1.4086	
CAMK2D	 817	 1.3780	 -1.8171	 -1.0562	 -1.4306	 -1.3717	
CAMK4	 814	 1.1173	 -1.0041	 1.0244	 1.0170	 1.4807	
PPP3CA	 5530	 -1.0679	 -1.1391	 -4.4206	 -1.0901	 -1.1414	
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NFkB1	 4790	 -1.8829	 1.6466	 1.8537	 -1.3429	 -1.1220	
NFkB2	 4791	 -1.9227	 1.1474	 3.0284	 -1.3349	 -1.4022	
RELA	 5970	 1.0161	 1.3137	 3.5154	 1.4552	 -1.0315	
RELB	 5971	 -1.4547	 1.3258	 2.4936	 1.0235	 -1.0003	
REL	 5966	 -1.0572	 1.2662	 -1.3225	 1.0080	 1.0842	
NFATC1	 4772	 1.0171	 2.2826	 1.1181	 1.0658	 1.3799	
NFATC2	 4773	 2.2980	 1.9122	 -1.0952	 -1.2216	 1.4803	
NFATC3	 4775	 1.4524	 1.1518	 -1.5166	 1.2830	 1.2650	
NFATC4	 4776	 -1.1882	 -1.1059	 -1.2274	 -1.2375	 -1.1479	
CREB1	 1385	 -1.5866	 -1.7637	 -1.2734	 -1.3750	 -1.4478	
MAPK1	 5594	 1.1860	 1.0449	 -1.4963	 -1.2695	 -1.4842	
MAP3K7	 6885	 1.0506	 1.0291	 -1.0495	 1.2353	 1.0365	
NLK	 51701	 2.2148	 1.0336	 1.1425	 1.7717	 1.0901	
HIPK2	 28996	 1.8257	 -1.0352	 -1.7297	 1.3915	 1.1315	
















Wnt	1	 7471	 1.0097	 -1.1544	 -1.1480	 1.0021	
Wnt	2	 7472	 -1.0224	 -1.0892	 -1.0734	 -1.0600	
Wnt	2b	 7482	 -1.0438	 -1.3770	 -1.2097	 -1.3406	
Wnt3	 7473	 -1.0000	 -1.0751	 -1.0061	 -1.0227	
Wnt	3a	 89780	 1.0786	 1.1578	 -1.0093	 -1.0189	
Wnt	4	 54361	 -1.0034	 1.0307	 -1.0648	 -1.0823	
Wnt	5a	 7474	 -1.0080	 -1.0503	 1.2209	 6.2926	
Wnt	5b	 81029	 -1.0824	 -1.1094	 -1.0041	 1.1526	
Wnt	6	 7475	 -1.1454	 -1.2974	 -1.2274	 -1.1001	
Wnt	7a	 7476	 -1.0903	 1.0194	 -1.0115	 1.0568	
Wnt	7b	 7477	 -1.0664	 1.1921	 1.0045	 1.2180	
Wnt	8a	 7478	 1.1079	 1.0210	 1.1149	 1.0452	
Wnt	8b	 7479	 1.0430	 -1.0117	 1.0118	 1.0170	
Wnt	9a	 7483	 1.0289	 -1.2044	 -1.0915	 -1.0406	
Wnt	9b	 7484	 -1.0428	 -1.1106	 -1.0676	 1.0624	
Wnt	10a	 80326	 -1.3670	 -1.1560	 -1.3498	 -1.3330	
Wnt	10b	 7480	 -1.2812	 -1.1624	 -1.2105	 -1.1946	
Wnt	11	 7481	 -1.1320	 -1.1984	 -1.0435	 1.0661	
Receptors	
Fzd1	 8321	 -1.0349	 -1.0299	 -1.0823	 -1.0394	
Fzd2	 2535	 -1.1635	 -1.4565	 -1.1449	 1.3873	
Fzd3	 7976	 1.3665	 1.0812	 -1.0461	 1.7617	
Fzd4	 8322	 -1.0897	 -1.1428	 1.0094	 -1.1865	
Fzd5	 7855	 -1.2693	 -1.4711	 -1.1802	 1.0222	
fzd6	 8323	 1.0141	 1.0409	 -1.0227	 -1.1573	
Fzd7	 8324	 -1.0589	 -1.0328	 -1.0418	 1.1079	
Fzd8	 8325	 -1.3583	 -1.2150	 -1.1282	 -1.0574	
Fzd9	 8326	 -1.0458	 -1.2537	 -1.0551	 1.0256	
Fzd10	 11211	 1.0678	 -1.3507	 -1.0507	 -1.1383	
Co-receptors	
LRP5	 4041	 1.0912	 1.0100	 -1.0408	 1.1721	
LRP6	 4040	 -1.0158	 -1.0174	 -1.0934	 1.3216	
LRP1	 4035	 -2.4504	 -1.6889	 -1.1696	 -1.0803	
Kremen	1	 83999	 1.0218	 1.0004	 -1.0258	 1.0948	
Kremen	2	 79412	 -1.0196	 -1.1387	 -1.0224	 -1.1078	
RYK	 6259	 -1.4538	 1.5468	 1.1389	 1.5257	
ROR1	 4919	 -1.0267	 -1.1371	 -1.0253	 1.0990	
ROR2	 4920	 -1.0104	 -1.0176	 1.0526	 -1.2039	
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VANGL1	 81839	 1.0120	 -1.1749	 -1.0265	 -1.0991	
VANGL2	 57216	 -1.0823	 -1.0346	 1.0867	 -1.0855	
CELSR1	 9620	 -1.2823	 1.0675	 -1.0670	 -1.1313	
CELSR2	 1952	 -1.0539	 -1.1833	 -1.1143	 1.1074	
CELSR3	 1951	 -1.0653	 -1.1039	 -1.0586	 -1.0636	
PTK7	 5754	 -1.0413	 -1.2401	 -1.0548	 1.0258	
SDC1	 6382	 -1.1586	 -1.2876	 -1.1446	 -1.1348	
SDC2	 6383	 -2.0238	 -3.0293	 1.1840	 2.4422	
SDC3	 9672	 -13.9840	 -17.7616	 -2.2844	 -1.2611	
SDC4	 6385	 -3.3641	 -5.2096	 -1.1604	 -1.2838	
GPC2	 221914	 1.0280	 -1.1169	 1.0218	 -1.0776	
GPC3	 2719	 1.0086	 1.0355	 -1.0112	 -1.0938	
GPC4	 2239	 -1.0581	 -1.0137	 1.0073	 -1.2177	
GPC5	 2262	 1.0165	 1.0211	 -1.0607	 -1.0976	
GPC6	 10082	 -1.0489	 1.0607	 1.0356	 1.1023	
GPC1	 2817	 -1.2736	 -1.1863	 -1.1308	 1.0234	
CD44	 960	 1.7607	 2.3867	 1.6069	 1.3199	
Inhibitors	
Dkk1	 22943	 -1.1640	 1.0137	 -1.0596	 1.0133	
Dkk2	 27123	 1.0489	 -1.0804	 1.0889	 1.0432	
Dkk3	 27122	 -1.1317	 -1.1360	 -1.0182	 -1.1449	
Dkk4	 27121	 -1.1292	 -1.0598	 -1.1939	 1.1142	
WIF1	 11197	 -1.0493	 1.0038	 1.0410	 -1.2619	
sFRP1	 6422	 -1.1710	 1.0444	 -1.1043	 1.0285	
sFRP2	 6423	 -1.1927	 -1.2204	 -1.2165	 -1.0340	
sFRP3	 2487	 -1.1185	 -1.0538	 -1.0984	 -1.0177	
sFRP4	 6424	 -1.0741	 -1.0741	 -1.1922	 -1.0948	
sFRP5	 6425	 -1.0412	 -1.1051	 1.0468	 -1.0391	
Shisa2	 387914	 1.0506	 -1.0021	 1.0746	 1.0431	
Shisa3	 152573	 -1.0619	 -1.1272	 -1.1695	 -1.1468	
CTHRC1	 115908	 -1.2800	 -1.2979	 -1.1785	 -1.0866	
IGFBP1	 3484	 -1.0606	 -1.0005	 -1.1331	 -1.0923	
IGFBP2	 3485	 -1.0713	 -1.1487	 -1.0785	 1.5769	
IGFBP4	 3487	 -2.1345	 -2.3517	 -1.7152	 -1.2767	
IGFBP6	 3489	 -1.1611	 1.7273	 -1.0471	 1.2318	
CER1	 9350	 1.0559	 -1.1610	 1.0868	 -1.1534	
SOST	 50964	 -1.0677	 -1.0641	 -1.0556	 1.0414	
SOSTDC1	 25928	 -1.1579	 1.0825	 -1.0490	 -1.0792	
TPBG		 7162	 -1.0855	 -1.1817	 -1.0269	 -1.1761	
APCDD1	 147495	 -1.1348	 -1.2389	 -1.1245	 1.1224	
TRABD2A		 129293	 1.3821	 -1.1138	 -1.0627	 3.5819	
agonists/	positive	modulators	
NDP	 4693	 -1.0369	 1.0240	 -1.0718	 2.0848	
RSPO1	 284654	 1.0478	 -1.1746	 -1.0174	 -1.0283	
RSPO2	 340419	 1.0370	 -1.0039	 -1.0317	 -1.0654	
RSPO3	 84870	 -1.2302	 -1.0685	 -1.1931	 -1.0999	
RSPO4	 343637	 1.0945	 -1.0467	 1.0296	 1.0660	
ß-Catenin	dependent	signalling	
Dvl1	 1855	 -1.1003	 -1.1709	 -1.0041	 1.0043	
Dvl2	 1856	 1.0455	 -1.1767	 -1.0992	 -1.0679	
Dvl3	 1857	 -1.2685	 -1.3125	 1.1232	 1.0129	
GSK3ß	 2932	 1.2338	 1.8717	 -1.0518	 -1.0684	
Axin	1	 8312	 1.2076	 1.1760	 1.0062	 1.1292	
Axin	2	 8313	 1.0350	 -1.0332	 1.0269	 1.0315	
APC	 324	 1.0375	 2.2416	 -1.0043	 1.0717	
CSNK1A1	 1452	 1.8013	 1.5521	 1.3138	 1.1535	
CSNK1E	 1454	 1.6840	 -2.0421	 1.3688	 1.2844	
CSNK1D	 1453	 1.0470	 1.1399	 1.0297	 -1.0389	
CSNK2A1	 1457	 2.6044	 1.8369	 1.4823	 2.0097	
CSNK2A2	 1459	 1.1685	 1.1476	 1.2627	 1.0946	
CSNK2B	 1460	 1.0833	 1.1026	 1.0244	 1.5215	
CTNNB1	 1499	 -1.3528	 -1.8149	 1.0964	 -1.1370	
CTNNBIP1	 56998	 1.0367	 -1.1387	 1.0184	 -1.1564	
NDRG1	 10397	 1.3675	 -1.2411	 1.1185	 -1.0052	
NDRG2	 57447	 13.6004	 -3.6222	 2.6683	 5.0442	
FRAT1	 10023	 1.4554	 2.5653	 -1.1292	 1.1066	
FRAT2	 23401	 1.7967	 1.9805	 1.1342	 1.5524	
PAK4	 10298	 1.0538	 1.0361	 -1.0052	 -1.0163	
AKT1	 207	 -1.5811	 -1.3680	 -1.1693	 1.1469	
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AKT2	 208	 1.7915	 1.8000	 1.1900	 -1.0811	
AKT3	 10000	 1.0042	 1.7683	 1.0245	 -1.9218	
ILK	 3611	 1.3884	 1.1856	 1.0791	 -1.2412	
CXXC4	 80319	 -1.0787	 -1.1329	 -1.0647	 1.0324	
SUMO1	 7341	 1.4611	 -1.2652	 1.1000	 -1.0351	
RANBP2	 5903	 -1.8099	 -2.2638	 -1.2854	 1.1359	
SENP2	 59343	 1.2568	 1.3686	 1.2128	 1.1050	
BTRC	 8945	 -1.5329	 1.0744	 1.0409	 1.3042	
SKP1	 6500	 -1.0166	 -1.0535	 -1.0877	 1.3078	
CUL1	 8454	 1.2999	 -1.2547	 1.4976	 1.3651	
NKD1	 85407	 1.0227	 -1.0490	 -1.0427	 -1.0767	
ARRB1	 408	 1.5494	 2.9757	 -1.0999	 -1.2502	
ARRB2	 409	 1.1524	 1.5570	 -1.0507	 -1.4050	
MACF1	 23499	 -1.0623	 1.5709	 -1.1375	 -1.3735	
PPP1CA	 5499	 2.1597	 2.5729	 1.4084	 -1.0946	
PPP1CB	 5500	 1.2699	 1.3017	 1.0037	 1.0019	
PPP1CC	 5501	 1.4864	 1.8177	 1.1833	 1.0558	
PPP2R5B	 5526	 -1.0427	 1.1492	 1.0507	 -1.0998	
PPP2CB	 5516	 -1.2115	 -1.1894	 -1.1775	 -1.1469	
PPP2CA	 5515	 1.3410	 1.4718	 1.1537	 -1.0081	
PPP3CB	 5532	 1.4256	 1.7219	 1.1706	 -1.1373	
DAB2	 1601	 -8.9419	 -41.7488	 -2.0490	 -1.6478	
TCF1	 6927	 -1.1087	 -1.0798	 -1.0857	 1.0309	
TCF3	 6929	 1.4746	 1.1788	 -1.0796	 1.1391	
TCF4	 6925	 -2.3677	 -5.3755	 -1.6344	 1.0000	
LEF1	 51176	 -1.0256	 1.0626	 -1.0399	 -1.9252	
TCF7L1	 83439	 -1.1257	 -1.0008	 -1.0836	 -1.0007	
TCF7L2	 6934	 -7.2930	 10.9486	 -1.5495	 -1.7468	
TLE1	 7088	 -1.1562	 -1.1055	 -1.1633	 4.4839	
TLE2	 7089	 -1.1277	 -1.1117	 -1.0439	 -1.1298	
TLE3	 7090	 -1.2666	 -1.4523	 1.3582	 -1.6283	
TLE4	 7091	 1.7511	 5.0735	 1.4129	 -1.0544	
CDX1	 1044	 -1.0217	 -1.1464	 -1.0495	 -1.1573	
BCL9	 607	 -1.1029	 -1.1549	 1.0165	 1.5439	
PIAS4	 51588	 1.1418	 1.5378	 1.1064	 -1.0070	
FHL2	 2274	 -1.0335	 -1.1472	 -1.1182	 1.0811	
TAX1BP3	 30851	 1.0130	 -1.3228	 1.0601	 1.1446	
SALL1	 6299	 -1.0840	 -1.0511	 -1.1329	 1.0422	
SALL4	 57167	 1.0180	 -1.2479	 -1.0865	 1.1593	
MAP1B	 4131	 -1.1177	 -1.0840	 1.0195	 -1.0332	
PCP	signalling	
ANKRD6	 22881	 -1.1921	 -1.0092	 -1.0709	 -1.2642	
DAAM1	 23002	 1.3875	 1.2873	 1.0657	 2.5715	
DAAM2	 23500	 1.0333	 -1.0028	 -1.0796	 -1.0499	
RHO	A	 387	 1.3881	 1.4257	 1.2972	 1.0488	
RHO	B	 388	 -2.7277	 -1.2100	 -1.2101	 -1.3863	
ROCK1	 6093	 1.3576	 1.3783	 1.1282	 1.0642	
ROCK2	 9475	 1.3726	 1.6438	 1.0249	 1.4028	
RAC1	 5879	 1.6136	 -1.2333	 1.3042	 -1.1747	
RAC2	 5880	 3.8572	 6.4737	 1.4315	 1.5024	
RAC3	 5881	 1.2227	 1.3297	 1.0410	 1.0900	
MAP2K7	 5609	 1.1772	 1.2152	 1.0743	 1.0392	
MAP2K4	 6416	 1.6228	 1.7046	 1.2000	 1.2608	
MAP3K4	 4216	 1.8839	 1.4221	 1.0294	 1.3378	
MAPK8	 5599	 1.4700	 1.5345	 1.3773	 -1.4576	
MAPK9	 5601	 1.2817	 1.3061	 1.2371	 1.3208	
MAPK10	 5602	 -1.0157	 1.1798	 1.0655	 -1.2491	
JUN	 3725	 -4.5396	 -8.5569	 -1.0195	 1.0658	
ATF2	 1386	 1.0757	 -1.1054	 1.1084	 -1.1124	
CDC42	 998	 1.2107	 -1.0321	 1.0517	 1.0262	
MARK2	 2011	 1.9981	 2.3728	 1.5145	 1.1750	
Ca-Signalling	
PLCB1	 23236	 -1.0711	 -1.0142	 1.0832	 1.4089	
PLCB2	 5330	 1.5102	 1.7951	 -1.0470	 1.2400	
PLCB3	 5331	 1.1409	 -1.1602	 -1.0389	 -1.1196	
PLCB4	 5332	 -1.1018	 -1.0804	 -1.1142	 -1.0168	
PLCG1	 5335	 -1.3671	 -1.2939	 -1.0268	 1.0632	
PLCG2	 5336	 1.1676	 1.6333	 -1.0479	 1.0387	
PLCD1	 5333	 -1.0294	 -1.0821	 1.0977	 1.1187	
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PLCD3	 113026	 -1.0137	 -1.0446	 -1.0161	 1.0868	
PLCD4	 84812	 -1.0273	 -1.0314	 -1.1525	 -1.1341	
PLCE1	 51196	 1.0021	 1.0926	 -1.0255	 -1.0663	
PRKCA	 5578	 1.3714	 -1.4873	 1.0023	 1.6590	
PRKCB	 5579	 3.9927	 7.5222	 1.7442	 -1.6910	
PRKCG	 5582	 1.0591	 -1.0952	 1.0456	 -1.0857	
CAMK1	 8536	 1.0037	 2.3223	 1.0299	 1.4221	
CAMK1D	 57118	 1.8969	 1.4238	 1.4937	 1.1630	
CAMK1G	 57172	 -1.1636	 -1.0564	 -1.0457	 -1.1238	
CAMK2A	 815	 -1.2072	 -1.0568	 1.0183	 1.0790	
CAMK2B	 816	 1.0781	 -1.0263	 -1.0593	 -1.1159	
CAMK2G		 818	 1.5570	 -1.1664	 1.0419	 -1.0961	
CAMK2D	 817	 -1.5758	 -2.5413	 1.2151	 1.7960	
CAMK4	 814	 -1.0485	 -1.1461	 -1.0883	 -1.4048	
PPP3CA	 5530	 2.0980	 1.8450	 1.5470	 1.0562	
NFkB1	 4790	 1.6854	 -1.0498	 1.6017	 -1.7144	
NFkB2	 4791	 1.0364	 -1.7759	 1.1308	 -1.3089	
RELA	 5970	 1.0204	 1.1109	 1.0592	 1.0439	
RELB	 5971	 -1.0420	 -1.3304	 -1.0693	 -1.3590	
REL	 5966	 1.0393	 -1.0561	 1.1015	 -1.1801	
NFATC1	 4772	 -1.5256	 2.5389	 -1.1689	 -1.4578	
NFATC2	 4773	 1.3582	 -6.7436	 -1.2706	 1.4631	
NFATC3	 4775	 1.4056	 1.6297	 1.0922	 1.1901	
NFATC4	 4776	 1.0049	 -1.0797	 -1.0440	 1.0244	
CREB1	 1385	 1.1763	 1.8634	 -1.0683	 -1.1082	
MAPK1	 5594	 1.9619	 3.0605	 1.1845	 1.8177	
MAP3K7	 6885	 1.2715	 2.0198	 -1.0133	 -1.0448	
NLK	 51701	 -1.1397	 1.1441	 -1.0498	 1.9392	
HIPK2	 28996	 -1.0261	 1.2703	 1.0243	 1.5712	












Wnt	1	 7471	 -1.133980143	 -1.115985825	 -1.029608124	
Wnt	2	 7472	 -1.324275188	 -1.245568656	 1.000790296	
Wnt	2b	 7482	 -1.383356436	 1.195510709	 1.388362855	
Wnt3	 7473	 -1.303414366	 -1.18008834	 1.164342384	
Wnt	3a	 89780	 #N/A	 #N/A	 #N/A	
Wnt	4	 54361	 -1.168875127	 -1.170559825	 -1.005386424	
Wnt	5a	 7474	 2.967342144	 6.876444758	 2.299245364	
Wnt	5b	 81029	 1.066702146	 1.403380922	 1.249449144	
Wnt	6	 7475	 1.057031097	 -1.07443072	 -1.248936964	
Wnt	7a	 7476	 -1.208725642	 -1.112176136	 -1.02900337	
Wnt	7b	 7477	 -1.455952281	 -1.445384083	 -1.004953069	
Wnt	8a	 7478	 1.122277964	 1.073397815	 1.093807796	
Wnt	8b	 7479	 -1.555566312	 -1.427779097	 1.047735221	
Wnt	9a	 7483	 #N/A	 #N/A	 #N/A	
Wnt	9b	 7484	 -1.336612456	 -1.290677636	 1.012397217	
Wnt	10a	 80326	 -1.026980859	 1.013708925	 1.110479976	
Wnt	10b	 7480	 -1.761407872	 -1.581129476	 1.066790244	
Wnt	11	 7481	 -1.373157757	 -1.390156425	 -1.015667923	
Receptors	
Fzd1	 8321	 3.584257605	 1.849677915	 -2.010417659	
Supplementary	data	
	 	 	101	
Fzd2	 2535	 1.382497028	 2.303297739	 1.800645271	
Fzd3	 7976	 -1.277587363	 -1.87702466	 -1.533562287	
Fzd4	 8322	 1.423966297	 -1.308237859	 -2.083311916	
Fzd5	 7855	 -1.634196906	 -1.947267112	 -1.258913966	
fzd6	 8323	 -1.294774616	 1.060103946	 1.515763069	
Fzd7	 8324	 -1.115610105	 -1.369425415	 -1.251774174	
Fzd8	 8325	 1.270067557	 -1.071674828	 -1.336411161	
Fzd9	 8326	 -1.044390052	 -1.1607386	 -1.055789619	
Fzd10	 11211	 1.012074109	 1.025773762	 1.034965364	
Co-receptors	
LRP5	 4041	 1.452710066	 1.102076251	 -1.395097147	
LRP6	 4040	 1.466950006	 -1.138501484	 -1.877185505	
LRP1	 4035	 1.380646437	 2.375572422	 1.640301972	
Kremen	1	 83999	 -1.365676664	 -1.253400595	 1.046379683	
Kremen	2	 79412	 -1.22663849	 -1.062784499	 1.168823393	
RYK	 6259	 1.004126323	 1.073230925	 1.046274711	
ROR1	 4919	 1.107936489	 1.120996208	 1.003997867	
ROR2	 4920	 1.246196506	 1.446230373	 1.431407663	
VANGL1	 81839	 1.365706487	 1.180956609	 -1.152042507	
VANGL2	 57216	 -1.291596448	 1.016583275	 1.355722227	
CELSR1	 9620	 -1.4027793	 -1.261592842	 1.036283093	
CELSR2	 1952	 1.461351444	 1.036603234	 -1.374416876	
CELSR3	 1951	 -1.203939888	 1.021429824	 1.123296299	
PTK7	 5754	 1.314843236	 1.125148787	 1.013381741	
SDC1	 6382	 -2.653625065	 -1.312103094	 1.841708379	
SDC2	 6383	 1.675387267	 1.424077117	 -1.350628384	
SDC3	 9672	 1.205074266	 1.511596329	 1.334483728	
SDC4	 6385	 -1.318786785	 -1.259788369	 1.120200438	
GPC2	 221914	 -1.252343651	 -1.111942655	 1.029825539	
GPC3	 2719	 -10.34923525	 -7.298622465	 1.816855872	
GPC4	 2239	 -1.713973771	 1.140729316	 1.399841684	
GPC5	 2262	 -21.44636268	 -14.44903445	 -1.001580361	
GPC6	 10082	 1.32757433	 1.113963397	 -1.406348327	
GPC1	 2817	 1.125962321	 1.476452189	 1.306008657	
CD44	 960	 3.635172769	 15.32325927	 4.476799056	
Antagonists	
Dkk1	 22943	 1.398918147	 1.98636612	 12.46478436	
Dkk2	 27123	 -1.152840138	 -1.233538254	 -1.226955505	
Dkk3	 27122	 8.778332478	 9.220783697	 1.08650795	
Dkk4	 27121	 -1.347272405	 -1.206882165	 1.174759914	
WIF1	 11197	 -2.769029059	 -2.673839412	 1.101479509	
sFRP1	 6422	 -5.763880963	 -7.132151556	 1.070088766	
sFRP2	 6423	 10.89794626	 6.780467736	 -1.727027119	
sFRP3	 2487	 6.70220794	 3.640778043	 -1.719907159	
sFRP4	 6424	 3.48080581	 3.389897133	 1.117281517	
sFRP5	 6425	 -1.230444446	 -1.189231739	 1.016892915	
Shisa2	 387914	 -6.127026881	 -6.633182403	 1.13942511	
Shisa3	 152573	 -4.264092225	 -6.062618983	 -1.407634887	
CTHRC1	 115908	 34.38466931	 99.39512642	 3.202101901	
IGFBP1	 3484	 -2.458884854	 18.98350353	 40.41981721	
IGFBP2	 3485	 1.202135667	 -1.171464323	 -1.017927391	
IGFBP4	 3487	 1.417368018	 1.14861181	 -1.149470495	
IGFBP6	 3489	 1.924971692	 3.518554816	 1.534162127	
CER1	 9350	 -1.622301362	 -1.622993816	 1.016844264	
SOST	 50964	 -5.385682106	 -6.543979511	 -1.144876174	
SOSTDC1	 25928	 -6.795064991	 -12.72653298	 -1.950021998	
TPBG		 7162	 2.312788181	 3.474359865	 1.621467976	
APCDD1	 147495	 6.103822689	 5.190308729	 -1.157545143	




NDP	 4693	 -1.096484654	 1.107123335	 1.526145594	
RSPO1	 284654	 -1.3649201	 -1.293597928	 1.060267233	
RSPO2	 340419	 -1.059399167	 -1.021525136	 1.056231263	
RSPO3	 84870	 -1.051008475	 1.769600894	 1.316544231	
RSPO4	 343637	 -1.431480644	 -1.203809198	 1.21129907	
ß-Catenin	dependent	signalling	
Dvl1	 1855	 1.289714447	 1.246211774	 1.107754455	
Dvl2	 1856	 1.028367491	 1.085761675	 1.005707339	
Dvl3	 1857	 1.491242996	 2.134870565	 1.500093647	
GSK3ß	 2932	 1.328278241	 1.323190456	 1.089648881	
Axin	1	 8312	 -1.196247428	 -1.14847243	 1.060728434	
Axin	2	 8313	 -1.258074717	 -1.200803178	 1.021873822	
APC	 324	 1.465982822	 1.23273068	 -1.277144188	
CSNK1A1	 1452	 1.311053249	 1.295546305	 1.009418706	
CSNK1E	 1454	 1.911017554	 1.748559183	 -1.079365007	
CSNK1D	 1453	 1.69226951	 2.129454545	 1.154614177	
CSNK2A1	 1457	 1.401391878	 1.753027332	 1.255121631	
CSNK2A2	 1459	 1.248237741	 1.64423934	 1.171093671	
CSNK2B	 1460	 1.269759514	 1.134931547	 -1.088843294	
CTNNB1	 1499	 -2.66095652	 -3.898603411	 -1.262693819	
CTNNBIP1	 56998	 -1.358448567	 -1.361630174	 -1.014461705	
NDRG1	 10397	 2.290167694	 2.003738116	 -1.16936675	
NDRG2	 57447	 1.16828069	 -2.038885469	 -2.832898978	
FRAT1	 10023	 1.259220336	 1.256125631	 -1.025011507	
FRAT2	 23401	 1.550701092	 1.825562063	 1.08886623	
PAK4	 10298	 -1.240240289	 -1.323829306	 -1.046531636	
AKT1	 207	 2.390895553	 2.151040028	 -1.107751563	
AKT2	 208	 -1.335050618	 -1.198904989	 1.145284987	
AKT3	 10000	 2.37748746	 1.411176519	 -1.536053311	
ILK	 3611	 2.245027334	 2.013829177	 -1.22528232	
CXXC4	 80319	 -1.257415191	 -1.536550648	 -1.325931229	
SUMO1	 7341	 -1.121368304	 -1.251783678	 -1.043864812	
RANBP2	 5903	 -1.109158462	 -1.169324841	 -1.043454544	
SENP2	 59343	 -1.066203629	 1.053395277	 1.099180338	
BTRC	 8945	 -1.018086309	 -1.043770138	 -1.021840072	
SKP1	 6500	 1.063203059	 -1.152498308	 -1.221901265	
CUL1	 8454	 1.704737398	 2.095852631	 1.179458761	
NKD1	 85407	 -1.373908261	 -1.268853517	 1.040940034	
ARRB1	 408	 1.809813068	 1.452289174	 -1.267615895	
ARRB2	 409	 2.029399769	 3.434748787	 1.580898944	
MACF1	 23499	 1.786425641	 1.506029338	 -1.22782369	
PPP1CA	 5499	 1.477688468	 1.71407989	 1.17414777	
PPP1CB	 5500	 -1.238201441	 -1.195191299	 1.108768723	
PPP1CC	 5501	 1.260405787	 1.250892278	 1.035899142	
PPP2R5B	 5526	 1.061451675	 1.025841853	 1.025026972	
PPP2CB	 5516	 -1.436446446	 -1.33886331	 -1.102953743	
PPP2CA	 5515	 -1.004758838	 1.072804763	 1.051081344	
PPP3CB	 5532	 1.080063556	 1.356917165	 1.236252359	
DAB2	 1601	 1.164301469	 -1.158955809	 -1.380338409	
TCF1	 6927	 -1.530051115	 -1.972436498	 -1.280701909	
TCF3	 6929	 1.084544628	 1.294155363	 1.180643626	
TCF4	 6925	 10.22102336	 5.189265059	 -1.922066902	
LEF1	 51176	 1.138632599	 1.657525087	 1.65601457	
TCF7L1	 83439	 2.248597044	 1.259975702	 -2.038217267	
TCF7L2	 6934	 1.462326866	 -1.162132728	 -1.601614088	
TLE1	 7088	 2.429193731	 2.155936325	 -1.193833056	
TLE2	 7089	 1.280791965	 -1.127047458	 -1.374994321	
TLE3	 7090	 1.496525347	 1.494982502	 1.074806545	
TLE4	 7091	 -1.183244107	 -1.091672674	 1.12347155	
CDX1	 1044	 -1.085536361	 -1.011578062	 1.150406159	
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BCL9	 607	 -1.362178286	 -1.741934664	 -1.091691886	
PIAS4	 51588	 -1.111491921	 -1.1980189	 1.038515881	
FHL2	 2274	 3.329528166	 8.329019353	 2.198952864	
TAX1BP3	 30851	 #N/A	 #N/A	 #N/A	
SALL1	 6299	 1.004734576	 -2.477178189	 -2.415650485	
SALL4	 57167	 -1.436634307	 -1.431046897	 -1.051475876	
MAP1B	 4131	 6.074013744	 5.238552109	 -1.069927648	
PCP	signalling	
ANKRD6	 22881	 1.742713169	 1.359020888	 -1.042948328	
DAAM1	 23002	 1.009453656	 -1.262825447	 -1.315831589	
DAAM2	 23500	 1.732905748	 1.207742125	 -1.31315434	
RHO	A	 387	 1.846909082	 2.110809094	 1.042177498	
RHO	B	 388	 1.520962404	 -1.716785354	 -2.500086048	
ROCK1	 6093	 1.584387054	 1.425687306	 -1.108313198	
ROCK2	 9475	 1.339074617	 1.247466827	 1.00111951	
RAC1	 5879	 1.328458805	 1.433274369	 1.060350703	
RAC2	 5880	 4.08874283	 10.07493166	 2.263784778	
RAC3	 5881	 -1.542901535	 -1.51462049	 1.137959544	
MAP2K7	 5609	 -1.027864834	 -1.005100529	 -1.014774998	
MAP2K4	 6416	 -1.099965766	 1.068826953	 1.052906644	
MAP3K4	 4216	 1.483073738	 1.194525514	 -1.262007554	
MAPK8	 5599	 -2.25872637	 -2.63432144	 -1.243079946	
MAPK9	 5601	 1.29004651	 1.355271919	 1.038577125	
MAPK10	 5602	 -2.524020898	 -3.432548437	 -1.454735636	
JUN	 3725	 1.988653599	 1.7417627	 -1.350791103	
ATF2	 1386	 1.234215251	 1.082645845	 -1.027613523	
CDC42	 998	 -1.139600981	 -1.018081185	 1.101781963	
MARK2	 2011	 2.126391661	 2.214945365	 1.031941706	
Ca-Signalling	
PLCB1	 23236	 2.777261538	 1.623132108	 -1.724282305	
PLCB2	 5330	 -1.321955152	 -1.141593069	 1.201913509	
PLCB3	 5331	 -1.244635264	 -1.067696636	 1.04100577	
PLCB4	 5332	 2.029270852	 8.627119408	 3.535088233	
PLCG1	 5335	 1.009942854	 1.016920234	 -1.044699153	
PLCG2	 5336	 -1.722484548	 -1.356941956	 1.116611218	
PLCD1	 5333	 -1.345298093	 -1.441158673	 -1.181675697	
PLCD3	 113026	 -1.100471874	 -1.008918092	 1.19476375	
PLCD4	 84812	 -4.312582026	 -2.698849939	 1.424287042	
PLCE1	 51196	 -1.393012619	 1.136634573	 1.355819519	
PRKCA	 5578	 -1.699574687	 -1.246047358	 1.405377313	
PRKCB	 5579	 1.197818149	 1.595511116	 1.349703551	
PRKCG	 5582	 -1.311002605	 -1.310415823	 1.062479787	
CAMK1	 8536	 1.828809625	 1.891619375	 -1.007996616	
CAMK1D	 57118	 2.026101077	 1.923216022	 -1.031548829	
CAMK1G	 57172	 -1.12031656	 -1.139301845	 1.009346511	
CAMK2A	 815	 -2.141586935	 -2.140552189	 1.031997465	
CAMK2B	 816	 -1.285865389	 -1.226629584	 1.092573587	
CAMK2G		 818	 -1.743880887	 -1.568126553	 1.132000332	
CAMK2D	 817	 -1.016006978	 -1.191151311	 -1.219818519	
CAMK4	 814	 -1.231335085	 -1.213443951	 -1.015567417	
PPP3CA	 5530	 1.073327679	 1.014770572	 -1.018062525	
NFkB1	 4790	 2.620207883	 2.512596401	 -1.150557457	
NFkB2	 4791	 1.712433148	 1.869465336	 1.392446338	
RELA	 5970	 1.355806855	 1.420662784	 1.020914462	
RELB	 5971	 1.64304941	 2.037120771	 1.279179867	
REL	 5966	 1.941812493	 2.411602709	 1.240428454	
NFATC1	 4772	 1.209499021	 1.161418352	 -1.080612511	
NFATC2	 4773	 1.579927484	 1.715789398	 1.133516808	
NFATC3	 4775	 1.241450506	 1.33321685	 1.001947506	
NFATC4	 4776	 -1.048379179	 -1.167421008	 -1.144693204	
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CREB1	 1385	 1.966645631	 1.845680333	 -1.127479107	
MAPK1	 5594	 1.941009924	 2.049992218	 1.088210692	
MAP3K7	 6885	 1.537663421	 1.7339144	 1.146743566	
NLK	 51701	 1.341225471	 1.207841684	 -1.191006666	
HIPK2	 28996	 2.757924464	 1.727160185	 -1.590288812	
























for	 the	 warm	 welcome	 into	 your	 working	 groups.	 Thank	 you,	 Alex	 for	 all	 the	 support	 regarding	 the	
migration	assays.	Thank	you,	Anke	for	truly	introducing	me	to	cell	culture.	Thank	you	Carsten,	for	guiding	

























bedient	 und	 alle	 Erkenntnisse,	 die	 aus	 dem	 Schrifttum	 ganz	 oder	 annähernd	




ähnlicher	 Form	 bei	 einer	 anderen	 Stelle	 zur	 Erlangung	 eines	 akademischen	 Grades	
eingereicht	wurde.	
	
	
München,	den	…..........................................	…...............................................	
(Unterschrift)	
